THE purpose of this review is to evaluate recent developments in our understanding of the inflammatory response to cardiac surgery. Scientific knowledge in this field is continually expanding, potentially significant advances are regularly reported, and this area constitutes a major interface of clinical and basic scientific research. The review is divided into four major sections. The first section describes the pathophysiology of the inflammatory response to cardiac surgery. Factors that influence the extent of the inflammatory response, including the immunomodulatory effects of drugs commonly administered perioperatively, are discussed in the second section. The third section examines the evidence that the inflammatory response contributes to adverse perioperative events, in particular organ dysfunction, while the final section evaluates potential therapeutic strategies to control this response. The review concludes with a summary of potential future research directions and key deficiencies in our knowledge regarding the inflammatory response to cardiac surgery.

The Systemic Inflammatory Response

Inflammation is the body’s response to tissue injury and is a rapid, highly amplified, controlled humoral and cellular response. While the term “sepsis” has classically been utilized to imply a clinical response to infection, a similar response may arise in the absence of infection. In fact, patients who appear to have sepsis but have negative microbial cultures have similar morbidity and mortality rates to the respective culture-positive populations. This has led to the understanding that this process is a generalized, nonspecific inflammatory response to injury and prompted a diagnostic reclassification of these events into a pathophysiological continuum by the American College of Chest Physicians–Society of Critical Care Medicine Consensus Conference Committee in 1991 (table 1). The term “systemic inflammatory response syndrome” (SIRS) has been proposed to describe the entry point to this continuum, an entity that overlaps with normal postoperative physiology. SIRS is a nonspecific, generalized inflammatory process, independent of the causative factors, and is of importance for several reasons. It is a sensitive if nonspecific indicator of injury. The classification of severity of SIRS into uncomplicated SIRS, sepsis, severe sepsis, and septic shock based on the existence of documented infection or hypotension has prognostic significance. A frequent complication of SIRS is the development of organ dysfunction, including acute lung injury, shock, renal failure, and multiple organ dysfunction syndrome (MODS). Finally, long-term survival in patients developing SIRS may also be adversely affected. This is well documented in the context of sepsis, with the risk of death increased for up to 5 yr after the septic episode.

The Inflammatory Response to Cardiac Surgery

Cardiac surgery provokes a vigorous inflammatory response, which has important clinical implications. In the report from the Society of Thoracic Surgeons National Database, 20% (22,000 patients) of “low-risk” patients developed postoperative complications. The incidence of MODS following cardiopulmonary bypass (CPB) was 11%, with a mortality rate of 41% in these patients in another study. Acquired multiple organ dysfunction is the best predictor of mortality in cardiac surgical patients who require prolonged postoperative mechanical ventilation. Many aspects of a patient’s risk of serious...
Table 1. Criteria for Diagnosis of SIRS, Sepsis, and MODS\textsuperscript{2}

\begin{tabular}{l}
\textbf{SIRS:} diagnosis requires presence of two or more of the following: \\
Temperature > 38°C or < 36°C \\
Heart rate > 90 beats/min \\
Respiratory rate > 20 breaths/min or Paco\textsubscript{2} < 32 mmHg \\
Leukocytes > 12,000, < 4,000/mm\textsuperscript{3} or > 10\% immature (band) forms \\
\textbf{Sepsis:} SIRS with documented infection \\
\textbf{Severe sepsis:} sepsis associated with organ dysfunction, hypoperfusion or hypotension \\
\textbf{Septic shock:} sepsis with hypotension despite adequate resuscitation along with the presence of perfusion abnormalities \\
\textbf{MODS:} a state of altered organ function in an acutely ill patient such that homeostasis cannot be maintained without intervention
\end{tabular}

SIRS = systemic inflammatory response syndrome; MODS = multiple organ dysfunction syndrome.

perioperative complications are perceived as being relatively fixed (genotype, preoperative health status, surgical difficulty, etc.), but the degree to which these may be improved (e.g., hemodynamic optimization using pharmacologic or mechanical support) is still under assessment. The contribution of the inflammatory response to patient outcome is potentially remediable and therefore deserves attention.

Factors influencing incidence, severity, and clinical outcome of the inflammatory response, and in particular the reasons why certain patients develop life-threatening perioperative complications, are currently not well understood. Three separate perspectives contribute to our understanding of the link between the inflammatory response and adverse clinical sequela. First, the complex interaction of humoral proinflammatory and antiinflammatory molecules may influence the clinical presentation and course of SIRS, with the balance of proinflammatory and antiinflammatory cytokines determining the clinical course following cardiac surgery.\textsuperscript{7} Alternatively, changes in the time course, magnitude, or patterns of cytokine release following CPB may contribute to abnormalities in the inflammatory response to cardiac surgery.

Second, a “multiple-hit” scenario may be seen, whereby serious sequela develop after cardiac surgery as a result of adverse events, such as infection or ongoing organ hypoperfusion.\textsuperscript{1,8} The combination results in the conversion of an inherently self-limiting, tightly controlled homeostatic response to an uncontrolled destructive process resulting in organ dysfunction.\textsuperscript{1,8,9} Potential mechanistic insights into the pathophysiologic basis for multiple hits include the ability of CPB to “prime” neutrophils, causing pulmonary leukosequestration,\textsuperscript{10} and enhanced cytokinin release following a subsequent insult.\textsuperscript{10}

Third, it has been suggested that there may be a fundamental misconception about the inflammatory response. The proinflammatory state, SIRS, may be only one aspect of a multifaceted response. The converse has been termed the compensatory antiinflammatory response syndrome.\textsuperscript{11} CPB-induced generalized immunosuppression may play an important role in the development of infectious complications.\textsuperscript{12} Cumulatively, these responses represent the body’s attempt to reestablish homeostasis and may clinically manifest as predominantly proinflammatory (SIRS), antiinflammatory (compensatory antiinflammatory response syndrome), or an intermediate mixed response.\textsuperscript{11}

Relevance to the Anesthesiologist

As perioperative physicians, anesthesiologists contribute to the management of the patient when adverse sequelae of CPB may pose a significant threat. Anesthesiologists are well positioned to minimize the risk of adverse sequelae resulting from the inflammatory response to CPB by reducing perioperative risk factors. Many drugs administered during the perioperative period, particularly for the purposes of anesthesia and sedation, possess potentially important immunomodulatory effects. Anesthesiologists may be best placed to properly evaluate and eventually implement therapeutic strategies, particularly as many potentially useful therapies seem poised to enter the clinical arena. Finally, a thorough knowledge of all aspects of the inflammatory response to CPB is mandatory if the anesthesiologist is to realize the goal of minimizing perioperative risk.

Pathophysiology of the Inflammatory Response to Cardiac Surgery

Factors That Activate the Inflammatory Response

Nonspecific activators of the inflammatory response include surgical trauma, blood loss or transfusion, and hypothermia. In addition, CPB may specifically activate the inflammatory response via at least three distinct mechanisms (fig. 1). One mechanism involves direct “contact activation” of the immune system following exposure of blood to the foreign surfaces of the CPB circuit. A second mechanism involves ischemia–reperfusion injury to the brain,\textsuperscript{13,14} heart,\textsuperscript{14,15} lungs,\textsuperscript{16} kidney,\textsuperscript{17,18} and liver\textsuperscript{19} as a result of aortic cross-clamping. Restoration of perfusion on release of the aortic cross-clamp is associated with activation of key indices of the inflammatory response.\textsuperscript{20,21}

Endotoxemia may indirectly activate the inflammatory cascade. Splanchnic hypoperfusion, a common finding during and following CPB,\textsuperscript{22} may damage the mucosal barrier, allowing gut translocation of endotoxin.\textsuperscript{23,24} Systemic endotoxin concentrations correlate closely with the degree of cardiovascular dysfunction following CPB,\textsuperscript{25,26} while low preoperative serum immunoglobul-
lin M antiendotoxin core antibody concentrations predict poor outcome. However, the importance of endotoxin in stimulating the inflammatory response to cardiac surgery remains in doubt, with conflicting evidence regarding the importance of gut translocation. In fact, endotoxin may be a contaminant of fluids, such as cardioplegia and circuit priming fluid, routinely used during CPB. The sole study to examine the incidence and time sequence of splanchic hypoperfusion (as measured by intramucosal pH), gut permeability, and endotoxia during CPB found no association between mucosal acidosis and either endotoxia or intestinal permeability.

Key Components of the Inflammatory Response

The Complement Cascade. Complement is activated during extracorporeal circulation, reperfusion of ischemic tissues, and heparin neutralization with protamine. Exposure of blood to the foreign surface of the extracorporeal circuit results in direct “contact” activation of the complement cascade, predominantly via the alternate pathway (fig. 2). The blood-gas interface of the CPB circuit may also play a role in complement activation. The formation of heparin–protamine complexes activates the complement cascade mainly via the classic (C4a) pathway. In the first 5 days following cardiac surgery, a second delayed increase in complement activation products is seen. This delayed activation of complement appears to be mediated by C reactive protein in response to heparin–protamine complexes.

The central role of complement in the inflammatory response to cardiac surgery has been demonstrated by the effects of complement-specific inhibitors. Soluble human complement receptor type 1 attenuates lung and myocardial injury, while blockade of C3a formation prevents activation of neutrophils, monocytes and platelets in models of CPB. Anti-C5a monoclonal antibodies attenuate CPB-mediated pulmonary, myocardial, mesenteric, and microvascular dysfunction. Specific blockade of the alternative pathway of complement activation by monoclonal antibodies to properdin causes near complete inhibition of C3a and C5b-9 formation and dramatically reduces platelet and neutrophil activation. Recombinant soluble complement receptor 1, C3-binding cyclic synthetic peptide, and antihuman C5 monoclonal antibody all prevent up-regulation of adhesion molecules necessary for neutrophils to bind to the CPB circuit and vascular endothelium, a necessary step in the injury process. Finally, increased plasma concentrations of C5b-9, a terminal complex of complement proteins C5 to C9, are seen during CPB (fig. 2). Selective blockade of C5b-9 formation by antihuman C8 monoclonal antibody inhibits platelet but not leukocyte activation in a model of simulated extracorporeal circulation.

The degree of complement activation in patients undergoing CPB has clinical significance. The degree of postoperative pulmonary shunt correlates with activation of the classic pathway by protamine–heparin complexes. Postoperative levels of C4d–C-reactive protein, a specific marker for C-reactive protein–mediated activation of complement, correlate with the incidence of postoperative arrhythmia following coronary artery bypass graft (CABG). Postoperative C3a concentrations may predict the probability of cardiac, pulmonary, renal, and hemostatic dysfunction and the likelihood of developing MODS in children. Strategies that improve CPB circuit biocompatibility reduce indices of complement activation and may decrease postoperative morbidity, particularly in high-risk patients. Anti-C5a antibody, which reduces sC5b-9 formation, significantly reduces myocardial injury, blood loss, and postoperative cognitive deficits in patients undergoing CPB.

The Cytokine Cascade. Cytokines are soluble proteins and polypeptides that act as paracrine messengers of the immune system and are produced by a large variety of cell types, including activated monocytes, tissue macrophages, lymphocytes, and endothelial cells. Individual cytokines may exert either proinflammatory or antiinflammatory effects. Cytokines are essential for immunologic and physiologic homeostasis, are normally subject to tight homeostatic control, and are

---

Anesthesiology, V 97, No 1, Jul 2002
produced in response to a variety of physiologic and pathologic stimuli.

Proinflammatory cytokines play a pivotal role in stimulating the inflammatory process, with plasma concentrations of specific cytokines, such as interleukin-1β (IL-1β) and interleukin-6 (IL-6), predictive of outcome in certain critically ill patient subgroups (table 2). Tumor necrosis factor α (TNF-α) and IL-1β are elevated early following cardiac surgery, with IL-6 and IL-8 peaking later. While a direct cause-and-effect relation has not been demonstrated, elevations of proinflammatory cytokines have been strongly associated with adverse outcome following cardiac surgery. Patients who develop SIRS demonstrate significant elevations in cytokine concentrations compared to patients with an uncomplicated course following cardiac surgery. Within the subgroup of cardiac surgical patients who develop SIRS, nonsurvivors had dramatically higher IL-8 and IL-18 concentrations compared to survivors. In addition, serum concentrations of IL-6 correlate with mortality following pediatric cardiac surgery.

The proinflammatory cytokine response to cardiac surgery is balanced by a phased antiinflammatory cytokine response, with soluble cytokine receptors, cytokine receptor antagonists, and antiinflammatory cytokines also produced in large quantities (table 3). Key antiinflammatory cytokines include interleukin-10 (IL-10), interleukin-1 receptor antagonist (IL-1ra), TNF soluble receptors 1 and 2 (TNFsr 1 and 2), and transforming growth factor β. IL-10 is a potent inhibitor of the production of TNF-α, IL-1β, IL-6, and IL-8. While the specific role of other antiinflammatory mediators remains undefined, it has been suggested the clinical prognosis following CPB may depend on the balance between proinflammatory and antiinflammatory cytokines.

**Nitric Oxide.** Nitric oxide (NO) is a ubiquitous biologic mediator that acts as a physiologic regulator and can be responsible for tissue damage. Physiologic regulatory functions include endothelial-mediated vasodilation in both the systemic and pulmonary circulations, potentially significant immunomodulatory functions, as well as protean roles in nociception, memory, and erectile function. NO may have several protective roles in the inflammatory response. NO-induced vasodilation may prevent accumulation of injurious mediators at the endothelium (fig. 3). NO may scavenge free radicals and...
prevent up-regulation of neutrophil CD11/CD18 adhesion molecules.\textsuperscript{58} Supplementation of cardioplegia and perfusate with an NO precursor (arginine) or NO donor (SPM-5185) has beneficial effects on postreperfusion neutrophil accumulation, endothelial function, and myocardial performance following experimental myocardial ischemia,\textsuperscript{59} possibly by inhibiting neutrophil adherence and cytotoxicity. The release of NO during CPB appears to be dependent on the type of bypass flow, with attenuation of basal NO release during nonpulsatile flow leading to end-organ functional capillary closure as a result of diminished vessel wall shear stress.\textsuperscript{60,61} This release of NO is considered to be physiologic, produced by endothelial constitutive NO synthase (cNOS),\textsuperscript{60,62} and its release appears to be a function of both the frequency and amplitude of the pulsatile flow.\textsuperscript{63}

The role of NO in the inflammatory response is complex, however, and NO has several potentially deleterious actions. Cytokine-induced decrements of myocardial function appear to be related to increases in myocardial inducible NO synthase (iNOS),\textsuperscript{64} which is up-regulated by CPB.\textsuperscript{65} Prevention of myocardial iNOS up-regulation may reduce hemodynamic instability post-CPB,\textsuperscript{65} while NOS inhibition can reverse refractory hypotension in established shock. NO is a highly reactive free radical and combines with a variety of molecules in vivo. While the free radical scavenging role of NO is generally protective,\textsuperscript{66} NO may combine with the free radical superoxide to form peroxynitrite, a more reactive and injurious free radical.\textsuperscript{66,67} Finally, NO appears to be a powerful direct cellular toxin, inactivating enzymes involved in glycolysis, the Krebs cycle, and the electron transport chain\textsuperscript{67} and reducing intracellular adenosine triphosphate and antioxidant concentrations, hence predisposing to cell death.

The timing, source, and quantities of NO produced may be the key to dissecting these apparently paradoxical roles. NO is produced constitutively in small (pico-molar) quantities by cNOS isoforms, such as the vascular endothelial isoform (ecNOS).\textsuperscript{57} The activity of ecNOS appears to be inhibited in the earliest phases of the inflammatory response, allowing both unopposed vasoconstrictive influences and increased leukocyte and platelet adhesiveness to the endothelium.\textsuperscript{57} The activity of ecNOS appears to be inhibited in the earliest phases of the inflammatory response, allowing both unopposed vasoconstrictive influences and increased leukocyte and platelet adhesiveness to the endothelium. However, within 4–8 h, iNOS is produced in a wide variety of tissues, including vascular smooth muscle, hepatocytes, and Kupffer cells,\textsuperscript{67,68} and produces NO at much higher (nanomolar) quantities. Cytokines, particularly IL-1\textbeta, play a pivotal role in the process of NO-induced inflammatory dilatation.\textsuperscript{69} The proinflammatory response, once fully developed, represents a high-output NO state.\textsuperscript{67} In fact, exhaled NO following initiation of CPB
may represent an index of severity of the inflammatory response,\(^7\) although this has been disputed.\(^7\)

**Coagulation–Fibrinolytic Cascades.** The coagulation–fibrinolytic cascades and the inflammatory response, while in many respects separate processes, are closely interconnected, with activation of coagulation a key component of the acute inflammatory response and *vice versa*. In this context, inflammation and coagulation should perhaps be considered different facets of the same host response to injury.

The coagulation system has traditionally been divided (for conceptual and practical purposes) into the intrinsic and extrinsic pathways, both of which lead to a final common pathway, and result, *via* thrombin generation, in the formation of an insoluble fibrin clot. Activation of coagulation after CPB had been thought to be predominantly due to activation of the intrinsic pathway *via* the contact system. In this paradigm, plasma factor XII was pivotal to this process, becoming adsorbed and activated on contact with the CPB circuit. However, patients with congenital deficiency of factor XII still generate thrombin following CPB.\(^7\) This suggests that the extrinsic pathway, which requires expression and activation of tissue factor, perhaps in response to inflammatory stimuli and oxidative or shear stress, may also be involved.\(^7\)

Hemostasis is mediated by a balance of procoagulant and anticoagulant forces, which normally coexist in a delicate balance. The coagulation cascade consists of inactive circulating precursors, which are sequentially activated *via* enzymatic cleavage, yielding an active serine protease that hydrolyses the next factor in the cascade. Thrombin, the end product, catalyzes the formation of insoluble fibrin from fibrinogen, which form the strands that bind the platelet plug. This process is normally controlled and limited to discrete sites of injury by modulators, including plasminogen activators, thrombomodulin, proteins C and S, and serine protease inhibitors such as antithrombin III.\(^7\) The fibrinolytic cascade, activated during coagulation, results in the formation of plasmin, which splits fibrinogen and fibrin, remodelling the formed clot and later removing the thrombus when the endothelium heals.

### Table 2. Key Proinflammatory Cytokines in the Immune Response to Cardiac Surgery

<table>
<thead>
<tr>
<th>Cytokine</th>
<th>Source</th>
<th>Functions</th>
<th>In Cardiac Surgery</th>
</tr>
</thead>
<tbody>
<tr>
<td>TNF-α</td>
<td>Macrophages</td>
<td>Primary mediator in inflammatory response</td>
<td>Elevated early following cardiac surgery(^5)</td>
</tr>
<tr>
<td></td>
<td>Monocytes</td>
<td>Provokes pathophysiologic effects of SIRS</td>
<td>(^2)</td>
</tr>
<tr>
<td></td>
<td>Natural killer cells</td>
<td>Proinflammatory cytokine release</td>
<td>(^3)</td>
</tr>
<tr>
<td></td>
<td>T cells and B cells</td>
<td>Neutrophil release (from bone marrow) and activation</td>
<td>(^4)</td>
</tr>
<tr>
<td></td>
<td>Mast cells</td>
<td>Macrophage/monocyte differentiation and activation</td>
<td>(^5)</td>
</tr>
<tr>
<td></td>
<td>Endothelial cells</td>
<td>Activates coagulation/complement cascades</td>
<td>(^6)</td>
</tr>
<tr>
<td></td>
<td>Endothelial cells</td>
<td>Endothelial adhesion molecule synthesis</td>
<td>(^7)</td>
</tr>
<tr>
<td></td>
<td>Endothelial cells</td>
<td>Acute phase protein production</td>
<td>(^8)</td>
</tr>
<tr>
<td></td>
<td>Endothelial cells</td>
<td>Endogenous pyrogen</td>
<td>(^9)</td>
</tr>
<tr>
<td>IL-1β</td>
<td>Macrophages</td>
<td>Primary mediator in inflammatory response</td>
<td>Elevated early following cardiac surgery(^5)</td>
</tr>
<tr>
<td></td>
<td>Monocytes</td>
<td>Initiation of cell mediated immune response</td>
<td>May predict outcome in certain critically ill patient subgroups(^5)</td>
</tr>
<tr>
<td></td>
<td>Endothelial cells</td>
<td>Activation of T cells and macrophages</td>
<td>(^10)</td>
</tr>
<tr>
<td></td>
<td>Endothelial cells</td>
<td>iNOS expression; prostaglandin production</td>
<td>(^11)</td>
</tr>
<tr>
<td></td>
<td>Endothelial cells</td>
<td>Inhibition of lipoprotein lipase</td>
<td>(^12)</td>
</tr>
<tr>
<td></td>
<td>Endothelial cells</td>
<td>Procoagulant activity</td>
<td>(^13)</td>
</tr>
<tr>
<td></td>
<td>Endothelial cells</td>
<td>Release of proinflammatory cytokines</td>
<td>(^14)</td>
</tr>
<tr>
<td></td>
<td>Endothelial cells</td>
<td>Endothelial adhesion molecule synthesis</td>
<td>(^15)</td>
</tr>
<tr>
<td></td>
<td>Endothelial cells</td>
<td>Acute phase protein production</td>
<td>(^16)</td>
</tr>
<tr>
<td></td>
<td>Endothelial cells</td>
<td>Endogenous pyrogen</td>
<td>(^17)</td>
</tr>
<tr>
<td>IL-6</td>
<td>Macrophages</td>
<td>Key later role in inflammatory cascade</td>
<td>Elevated later following cardiac surgery(^5)</td>
</tr>
<tr>
<td></td>
<td>Type 2 helper cells</td>
<td>Activation of lymphocytes</td>
<td>Myocardial depressant(^6)</td>
</tr>
<tr>
<td></td>
<td>Type 2 helper cells</td>
<td>Differentiation of B cells and antibody production</td>
<td>Serum concentrations may correlate with mortality following pediatric cardiac surgery(^1)</td>
</tr>
<tr>
<td></td>
<td>Type 2 helper cells</td>
<td>T-cell activation and differentiation</td>
<td>(^2)</td>
</tr>
<tr>
<td></td>
<td>Type 2 helper cells</td>
<td>Acute phase protein production</td>
<td>(^3)</td>
</tr>
<tr>
<td></td>
<td>Type 2 helper cells</td>
<td>Endogenous pyrogen</td>
<td>(^4)</td>
</tr>
<tr>
<td>IL-8</td>
<td>Macrophages</td>
<td>Key later role in inflammatory cascade</td>
<td>Elevated later following cardiac surgery(^5)</td>
</tr>
<tr>
<td></td>
<td>T cells</td>
<td>Chemotaxis of neutrophils, basophils, and T cells</td>
<td>Important role suggested in regulating neutrophil inflammatory response to cardiac surgery(^5)</td>
</tr>
<tr>
<td></td>
<td>T cells</td>
<td>Regulates neutrophil activity, including neutrophil chemotaxis, the neutrophil respiratory burst, transendothelial neutrophil migration, and neutrophil dependent plasma leak</td>
<td>Negative correlation between IL-8 and postoperative cardiac index(^5)</td>
</tr>
<tr>
<td></td>
<td>Endothelial cells</td>
<td></td>
<td>(^6)</td>
</tr>
</tbody>
</table>

TNF-α = tumor necrosis factor α; IL = interleukin; SIRS = systemic inflammatory response syndrome; iNOS = inducible nitric oxide synthase.
Several specific points regarding the complex interrelation between coagulation and inflammation, in the context of CPB, deserve attention. The endothelium is intricately involved in both processes (see Endothelium). Proinflammatory cytokines play a key role in initiating the coagulation process locally at sites of inflammation, by activation of the endothelium, induction of the expression of tissue factor, eliciting the expression of leukocyte adhesion molecules on the intravascular cell surfaces, and stimulating production of platelet-activating factors. This, combined with down-regulation of thrombomodulin expression and of the fibrinolytic and protein C anticoagulant pathways, alters the balance between procoagulant and anticoagulant activities, resulting in a markedly procoagulant state.

The coagulation system in turn impacts on the inflammatory response. Platelet activation at sites of tissue injury results in the release of multiple mediators that alter tissue integrity. Several key coagulation proteins, such as thrombin and factor Xa, have proinflammatory properties. Thrombin, formed following activation of the coagulation cascade, stimulates several cell chemotaxins and mitogens, which are responsible for the spreading of the lesion and the tissue repair process.

Heparin and protamine, which are used to modulate coagulation in almost all patients undergoing cardiac surgery, may have important immunomodulatory effects. Heparin appears to possess important antiinflammatory effects. Protamine neutralization of heparin may result in multiple cardiovascular effects, including increased pulmonary artery pressures and decreased systolic and diastolic blood pressure, myocardial oxygen consumption, cardiac output, heart rate, and systemic vascular resistance. Although protamine by itself has adverse effects, the heparin–protamine complex is particularly deleterious. The heparin–protamine interaction activates the inflammatory response by several mechanisms, including complement activation, histamine release, thromboxane and nitric oxide production, and antibody formation. The release of thromboxane may result in severe pulmonary hypertension. In a minority of patients, severe anaphylactoid reactions may result from the heparin–protamine interaction.

The balance of procoagulants and anticoagulants is profoundly disturbed in CPB patients. Activation of procoagulants such as thrombin mandates administration of anticoagulant drugs prior to CPB to prevent blood from clotting instantly on contact with the extracorporeal circuit. In addition, the stimulation of fibrinolysis during CPB appears to contribute to the postoperative coagulopathy commonly seen in these patients. Widespread vascular injury following CPB may result in uncontrolled platelet activation, thrombin generation, and disseminated intravascular coagulation. The resulting widespread fibrin deposition in the microvasculature may occlude microcirculatory flow and cause end-organ damage, which may progress to MODS and death.

The Endothelium. The vascular endothelium is a dynamic participant in cellular and organ function rather than a static barrier, as was once believed. It is intimately involved in a variety of physiologic and pathologic processes and has emerged as the central focus of many of the biologic events that affect the perioperative course.

Table 3. Key Antiinflammatory Cytokines in the Immune Response to Cardiac Surgery

<table>
<thead>
<tr>
<th>Cytokine</th>
<th>Source</th>
<th>Functions</th>
<th>In Cardiac Surgery</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL-10</td>
<td>Macrophages</td>
<td>Feedback role in limiting inflammatory response</td>
<td>Elevated early following cardiac surgery</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Potent inhibitor of TNF-α, IL-1β, IL-6, and IL-8 production/release</td>
<td>May attenuate neutrophil activation during CPB</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Down-regulates monocyte HLA-DR expression</td>
<td>Increased production post-CPB in steroid-treated patients</td>
</tr>
<tr>
<td>TGF-β</td>
<td>Macrophages</td>
<td>Down-regulates proinflammatory cytokine production</td>
<td>Elevated early following cardiac surgery</td>
</tr>
<tr>
<td></td>
<td>Lymphocytes</td>
<td>Attenuates lymphocyte activation</td>
<td>Attenuates lymphocytic response to cardiac surgery</td>
</tr>
<tr>
<td></td>
<td>Platelets</td>
<td>May have direct cardioprotective action</td>
<td>TGF-β expression in cardiac allografts associated with impaired graft function and limited survival</td>
</tr>
<tr>
<td>IL-1ra</td>
<td>Shed hydrophilic extracellular portion of receptor containing ligand binding site</td>
<td>Specific antagonist to IL-1β</td>
<td>Elevated early following cardiac surgery</td>
</tr>
<tr>
<td>TNFsr 1 and 2</td>
<td>Shed hydrophilic extracellular portion of receptor containing ligand binding site</td>
<td>Possible role in limiting inflammatory response by binding circulating IL-1β</td>
<td>Increased production post-CPB in steroid treated patients</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Specific antagonist to TNF-α</td>
<td>Elevated later following cardiac surgery</td>
</tr>
</tbody>
</table>

IL = interleukin; TNF-α = tumor necrosis factor α; HLA = human leukocyte antigen; CPB = cardiopulmonary bypass; TGF-β = transforming growth factor β; IL-1ra = interleukin 1 receptor antagonist; TNFsr = tumor necrosis factor soluble receptor.
of the cardiac surgical patient. The endothelium controls vascular tone and permeability, regulates coagulation and thrombosis, and directs the passage of leukocytes into areas of inflammation, through the expression of surface proteins and secretion of soluble mediators.

The inflammatory response to CPB is characterized by a state of widespread endothelial activation and diffuse endothelial dysfunction.  

Inflammatory mediators, including TNF-α and IL-1β, bind to specific receptors on the endothelium, initiating diverse signal transduction pathways, which in turn activate a specific set of genes within the nucleus of the endothelial cell, termed activation genes. The transcription factor NF-κB plays a pivotal role in the signal transduction process. When activated, it dissociates from the cytosolic inhibitory protein IκB, translocates to the endothelial cell nucleus, binds with specific DNA sequences, and alters the conformation of the basal transcriptional apparatus, resulting in the transcription of the activation genes. This process results in the translation of proteins, including adhesion molecules (e.g., E-selectin, intercellular adhesion molecule-1) and cytokines (e.g., IL-8), required for endothelial cell activation, a process that takes approximately 4 h and peaks at 8–24 h depending on the gene.

The activated endothelial cell plays a pivotal role in linking the inflammatory and coagulation systems, by expressing proteins central to the activation of coagulation and inflammation. Endothelial cell adhesion molecule expression mediates the interaction between the neutrophil and the endothelial cell (see The Cellular Immune Response), resulting in neutrophil adhesion, activation, and degranulation. This further damages the endothelium, causing diffuse capillary leak and edema formation. Endothelial injury results in the expression of tissue factor, augmented by IL-1β and TNF-α, which activates the extrinsic pathway of coagulation and may result in disseminated intravascular coagulation.

In addition, protein C, a key inhibitory regulator of hemostasis, is antagonized in inflammatory states, most probably by TNF-α, further shifting the balance toward a procoagulant state.

Vascular endothelium plays a central role in the pathogenesis of microcirculatory derangement following CPB. Endothelial regulation of local vascular tone (fig. 3) is mediated via a variety of endothelium-derived relaxing and contracting factors such as NO, prostacyclin, endothelium-derived hyperpolarizing factor, endothelin, and thromboxane A2. The increase in pulmonary vascular resistance following CPB is attributed to reduced NO release from dysfunctional pulmonary endothelium and is reversed by NO supplementation.

A complex interplay exists between impaired endothelial function, inflammation, and atherosclerosis in the pathogenesis of adverse cardiovascular events. Alterations in NO generation appear to underpin these interrelationships. Of particular concern, the inflammatory response to cardiac surgery may increase the risk of a postoperative cardiac event. Proinflammatory cytokines and endotoxin can impair endothelium-dependent dilatation, and the endothelium may lose its ability to respond to circulating hormones or autacoids. Studies of forearm vasoregulation demonstrate that IL-1β, TNF-α, and endotoxin cause prolonged but reversible impairment of endothelial relaxation, termed “endothelial stunning.” Proinflammatory cytokines inhibit production of NO and a vasodilator antplatelet prostanoid. Loss of the vasodilator and antithrombotic effects of NO may alter myocardial perfusion and expose preexisting atheroma to unopposed vasospastic and prothrombotic influences. This may explain the association between an acute inflammatory episode and a transient increase in the risk of a cardiovascular event.

In addition, endothelial dysfunction may limit the long-term success of cardiac surgery, particularly CABG, by contributing to the development of narrowing at graft anastomotic sites as a result of medial hyperplasia and by accelerating the progression of atherosclerosis. Abnormalities of endothelium-dependent vasodilation, including paradoxical vasconstrictor responses to, e.g., exercise, are often observed in the earliest stages of coronary artery disease. Long-term follow-up clinical studies demonstrate that this is associated with an increased rate of cardiovascular events. Endothelial dysfunction activates the inflammatory response, recruiting leukocytes and platelets to the arterial wall, which may initiate the formation of atherosclerotic plaque.

This process is particularly likely at sites of disturbed blood flow such as occur at graft anastomoses and is markedly potentiated by the presence of hypercholesterolemia. Endothelial dysfunction in hypercholesterolemic patients is in large part due to a reduced bioavailability of NO. In this regard, statins, which lower cholesterol, have been demonstrated to rapidly restore endothelial function, in part by directly up-regulating eNOS. This restoration of endothelial function results in improved myocardial perfusion, reduced myocardial ischemia, and reversal of atherosclerosis.

The Cellular Immune Response. The process of neutrophil–endothelial adhesion is an essential component of the inflammatory response leading to widespread endothelial damage and is now well understood, involving distinct phases of primary and secondary adhesion (fig. 4). In the noninflamed state the leukocyte travels at around 1,000 μm/s, along with the erythrocytes, in the center of the postcapillary venule. In the first phase, primary adhesion, the freely moving neutrophil is converted to the “rolling” state, in which it tumbles slowly (around 30 μm/s) along the endothelium. This is mediated by the expression of a family of adhesion molecules known as selectins. P- and E-selectin are expressed on the endothelium, and L-selectin is expressed on the neutrophils. These are involved in the
formation of loose bonds between the endothelium and the neutrophil, which slows down the passage of the leukocyte along the blood vessel wall. C5a, released on activation of the complement cascade following contact with the extracorporeal circulation, is a potent stimulant of P-selectin expression. P-selectin is stored preformed in cytoplasmic vacuoles (the Weibel Palade Bodies) and rapidly reaches the plasma membrane by exocytosis after endothelial cell activation. This may underlie the sudden leukosequestration in the pulmonary circulation, which occurs following initiation of CPB. This process of primary adhesion is later maintained by E-selectin, which must be produced de novo by the activated endothelium.

Secondary or tight adhesion of the neutrophil to the endothelium requires the action of the integrin family of cell surface receptor molecules. These macromolecules consist of two different protein chains (α and β) that are noncovalently associated and are expressed on the cell surface. One subfamily of integrins, which share the same β chain (CD18), is expressed only on leukocytes. CD11a/CD18 and CD11b/CD18 are expressed abundantly by neutrophils, the former at relatively constant concentrations, while expression of the latter is greatly enhanced by cytokines, such as IL-8 and C5a. The activated integrins bind to adhesive molecules expressed on the endothelial surface, in particular, intercellular adhesion molecule-1. CD11a/CD18 may also bind to a related adhesion molecule, intercellular adhesion molecule-2, and CD11b/CD18 may adhere to elements of the extracellular matrix, such as fibrinogen. The neutrophil becomes tightly adherent to the endothelium, flattens out, and eventually transmigrates out of the circulation, triggering activation and degranulation and further endothelial injury.

Adherence via CD11b/CD18 appears to prime the neutrophil to degranulate and undergo the respiratory burst. The primed neutrophils release cytotoxic proteases, such as elastase and myeloperoxidase, and reactive oxygen species resulting in damage to the vascular endothelium and surrounding tissues. This complex process of coordination of the function of adhesive molecules and regulation of the migration of neutrophils is modulated by chemokines, in particular, platelet activating factor, IL-8, and C5a. Therefore, in the absence of secondary insults, such as shock or infection, endothelial cells return to their resting state and lose their adhesive properties following return of cytokine and C5a concentrations to normal. This limits the inflammatory response in most patients undergoing cardiac surgery.

Secondary or tight adhesion of the neutrophil to the endothelium requires the action of the integrin family of cell surface receptor molecules. These macromolecules consist of two different protein chains (α and β) that are noncovalently associated and are expressed on the cell surface. One subfamily of integrins, which share the same β chain (CD18), is expressed only on leukocytes. CD11a/CD18 and CD11b/CD18 are expressed abundantly by neutrophils, the former at relatively constant concentrations, while expression of the latter is greatly enhanced by cytokines, such as IL-8 and C5a. The activated integrins bind to adhesive molecules expressed on the endothelial surface, in particular, intercellular adhesion molecule-1. CD11a/CD18 may also bind to a related adhesion molecule, intercellular adhesion molecule-2, and CD11b/CD18 may adhere to elements of the extracellular matrix, such as fibrinogen. The neutrophil becomes tightly adherent to the endothelium, flattens out, and eventually transmigrates out of the circulation.

Adherence via CD11b/CD18 appears to prime the neutrophil to degranulate and undergo the respiratory burst. The primed neutrophils release cytotoxic proteases, such as elastase and myeloperoxidase, and reactive oxygen species resulting in damage to the vascular endothelium and surrounding tissues. This complex process of coordination of the function of adhesive molecules and regulation of the migration of neutrophils is modulated by chemokines, in particular, platelet activating factor, IL-8, and C5a. Therefore, in the absence of secondary insults, such as shock or infection, endothelial cells return to their resting state and lose their adhesive properties following return of cytokine and C5a concentrations to normal. This limits the inflammatory response in most patients undergoing cardiac surgery.

The cellular immune system is central to the inflammatory response following cardiac surgery. Increased spontaneous activation of both granulocytes and macrophages is observed following CPB. Hyperstimulation of naive monocytes and granulocytes occurs following exposure to plasma from CPB patients. CPB activates monocytes and macrophages via increased monocyte chemoattractant factor production, and up-regulation of macrophage adhesion molecule expression and cytokine production. Increased concentrations of leukocyte adhesion molecules (selectins and integrins) have been demonstrated following CPB. During CPB, the neutrophils are primed for enhanced free radical generation, as evidenced by an enhanced oxidative burst response seen up to 24 h after CPB and demonstration of the release of intracellular lysosomal granular contents post-CPB. Elevated circulating neutrophil counts and

---

Fig. 4. This schematic diagram illustrates the neutrophil–endothelium interaction. Each neutrophil illustrates a key event, as it proceeds from left to right along the capillary. Briefly, neutrophils become tightly adherent to the endothelium in a 3-stage process. In the first stage, the freely moving neutrophil is converted to the “rolling” state, in which it moves slowly along the endothelium. The neutrophil loosely interacts with the endothelium via the expression of selectins on both the neutrophil and endothelial cell membranes. In the second stage, the expression of integrins on neutrophil and endothelium results in a tighter binding to the capillary wall. In the third stage, the neutrophil becomes tightly adherent to the endothelium and transmigrates out of the circulation, triggering activation and degranulation and further endothelial injury.
increased neutrophil aggregability, superoxide generation, and elastase release occur up to 24 h after surgery,\textsuperscript{103} with impaired oxidative function at 48 h postoperatively.\textsuperscript{104} This suggests a biphasic abnormality with potential early tissue cytotoxicity followed later by neutrophil dysfunction. In addition, reticuloendothelial Kupffer cells demonstrate greatly increased phagosomes following CPB,\textsuperscript{105} which may cause a relative “overuse” type of impairment of phagocytic activity.\textsuperscript{105,106}

The clinical importance of leukocytes in the inflammatory response to CPB is underscored by several findings. Pulmonary neutrophil sequestration has been demonstrated following CPB and is associated with evidence of severe histologic lung injury.\textsuperscript{107,108} Inhibition of neutrophil CD11/CD18 expression\textsuperscript{109} or function\textsuperscript{110} improves myocardial function following cardiac surgery. Blockade of neutrophil adhesion\textsuperscript{111} decreases pulmonary injury after CPB. Finally, strategies that deplete circulating leukocytes can attenuate organ injury and may improve patient outcome following CPB (see Therapeutic Strategies).\textsuperscript{112}

Factors Influencing the Extent of the Inflammatory Response to Cardiac Surgery

Preoperative Factors

Preexisting disorders may influence the inflammatory response to cardiac surgery. Disordered cytokine balance may be a pathophysiologic feature of ischemic heart disease.\textsuperscript{113} Patients with preoperative left ventricular dysfunction undergoing CPB appear to have a greater degree of proinflammatory cytokine release, which is associated with impaired hemodynamics and a higher incidence of perioperative complications.\textsuperscript{114} CPB appears to cause greater oxidative stress in patients with diabetes, and there are qualitative differences in the inflammatory response in diabetic patients.\textsuperscript{115} Poorly controlled diabetes impairs the inflammatory response.\textsuperscript{116}

The perioperative course of proinflammatory and antiinflammatory cytokine release in adult patients undergoing CABG does not differ with age.\textsuperscript{117}

Perioperative Hemodynamic Factors

Perioperative hemodynamic instability predicts morbidity and mortality following CPB,\textsuperscript{118–120} with low cardiac output syndrome the most common event leading to patient death.\textsuperscript{121} Strong clinical and experimental evidence links postoperative splanchnic hypoperfusion to the development of complications such as acute respiratory distress syndrome.\textsuperscript{16} Experimental splanchnic ischemia–reperfusion induces lung recruitment and sequestration of neutrophils,\textsuperscript{122} increased pulmonary iNOS expression,\textsuperscript{123} and free radical injury.\textsuperscript{124} Cytokines, particularly TNF-α, also appear central to this process.\textsuperscript{125,126} In addition, translocation of toxins and microbial flora may occur following ischemic compromise of the integrity of the mucosal barrier.

Gastric mucosal pH, as measured by gastric tonometry, provides an index of splanchnic perfusion.\textsuperscript{127} Gastric mucosal acidosis indicates inadequate oxygenation of splanchnic tissue and is common following weaning from CPB, even in the absence of gross hemodynamic instability.\textsuperscript{128} It is a highly sensitive predictor for complications,\textsuperscript{129} independent of clinical risk stratification, even during uneventful cardiac surgery with low expected mortality.\textsuperscript{130} Therapeutic strategies to maintain hemodynamic stability and minimize postoperative splanchnic ischemia may reduce postoperative complications.

Anesthetic Techniques

Thoracic Epidural Anesthesia.

Thoracic epidural anesthesia combined with general anesthesia for CABG decreased the perioperative stress response, as measured by plasma epinephrine, and may decrease postoperative myocardial and pulmonary injury.\textsuperscript{131} However, thoracic epidural anesthesia does not significantly alter the cytokine response to CPB.\textsuperscript{132}

Lung Management during Cardiopulmonary Bypass.

Apnea during CPB may lead to activation of lysosomal enzymes in the pulmonary circulation, which in turn are correlated with the degree of postoperative acute lung injury (ALI).\textsuperscript{133} This may be attenuated by a vital capacity maneuver performed before termination of the bypass,\textsuperscript{134} however, continuous positive airway pressure applied during CPB appears ineffective.\textsuperscript{135}

Anesthetic Agents and Adjuvant Drugs

Many of the drugs used to produce anesthesia and maintain postoperative sedation and analgesia possess immunomodulatory effects (table 4). The clinical implications of such effects, particularly in the context of CPB, remain unknown, with most data in this area to date confined to in vitro experiments. Nevertheless, developments in this emerging field are worthy of consideration in the light of their future therapeutic potential.

Propofol may enhance the antiinflammatory response to surgery by several mechanisms. Propofol may preserve hepatosplanchnic blood flow during CPB, thereby aiding maintenance of the mucosal barrier.\textsuperscript{136} It alters the balance between proinflammatory and antiinflammatory cytokines, increasing production of the antiinflammatory cytokine IL-10 and IL-1ra,\textsuperscript{137} while decreasing neutrophil IL-8 secretion,\textsuperscript{138} and scavenges reactive oxygen species.\textsuperscript{139} Low concentrations of propofol reduce neutrophil uptake in the coronary circulation following myocardial ischemia and reperfusion.\textsuperscript{140} However, this effect is abolished at higher propofol concentrations; this may be due to the propofol solvent Intralipid (Kabi Pharmacia, Uppsala, Sweden).\textsuperscript{140} Propofol impairs several aspects of monocyte and neutrophil function, including the respiratory burst,\textsuperscript{141,142} polarization,\textsuperscript{143} che-
motaxis, phagocytosis, and oxygen radical generation. Certain immunomodulatory effects of propofol, such as suppression of respiratory burst of neutrophils by propofol, may be caused by the solvent Intralipid, while other actions, such as its ability to scavenge free radicals, appears to be a property of propofol itself. Sodium thiopental impairs the neutrophil respiratory burst, polarization, chemotaxis, and adherence and coronary uptake of neutrophils following myocardial ischemia and reperfusion. At therapeutic concentrations, thiopental also inhibits the monocyte respiratory burst. The effect of thiopental on the respiratory burst of neutrophils appears less pronounced compared to propofol.

Ketamine attenuates the increase of serum IL-6 concentrations during and following CPB and reduces coronary uptake of neutrophils following myocardial ischemia and reperfusion. Ketamine affects E. coli clearance and neutrophil monocyte phagocytosis in vitro, although only in high concentrations. Methohexitone has only minimal effects on the respiratory burst of neutrophils in vitro. Opioids have multiple effects on the immune system, mediated indirectly via the central nervous system or through direct interactions with the cellular immune system. While the precise cellular mechanisms underlying the immunomodulatory effects of opioids are largely unknown, emerging evidence indicates that opioids share many properties with cytokines. Ultrasensitive affinity novel δ, μ, and κ opioid receptors have been demonstrated on inflammatory...
Granulocytes contain both opioid peptide selective δ 2 receptors (which stimulate chemotaxis) and opiate alkaloid-selective, opioid peptide-insensitive receptors (which inhibit cytokine-induced activation and chemotaxis).  

Morphine down-regulates the activity of lymphocytes, granulocytes, and macrophages, and suppresses the antibody response. Microinjection of morphine into the lateral ventricle of the rat induces pronounced, dose-dependent reductions in lymphocyte proliferation to T- and B-cell mitogens, natural killer cell cytotoxicity, and the production of IL-2 and interferon-γ. Morphine also increases the secretion of CRH, ACTH, and glucocorticoids, i.e., substances with inhibitory effects on the immune system. Certain immunomodulatory actions of morphine, including NO release and inhibition of cell adhesion, appear to be mediated specifically via the μ3 receptor.  

Fentanyl increases concentrations of IL-1ra in in vitro monocyte cultures. In an isolated blood primed CPB circuit, fentanyl increased CD11b, augmented the reduction in lymphocyte HLA-DR expression, and attenuated the increase seen in monocyte HLA-DR expression.  

However, fentanyl, unlike morphine, appears to lack the ability to bind to the μ3 receptor, diminishing its ability to down-regulate the inflammatory response to CPB. Midazolam, the best studied benzodiazepine, has little influence on host defense mechanisms. Midazolam decreases neutrophil IL-8 secretion in response to lipopolysaccharide but does not alter IL-8 production. Midazolam reduces postsischemic uptake of neutrophils in the coronary circulation following myocardial ischemia and reperfusion. Midazolam, at clinically relevant concentrations in vitro, does not attenuate neutrophil polarization and has minimal effects on the neutrophil respiratory burst, neutrophil phagocytosis, and clearance of E. coli.  

Sevoflurane, isoflurane, and enflurane decrease proinflammatory cytokine (IL-1β, TNF-α) release by human peripheral mononuclear cells in vitro. Isoflurane decreases alveolar macrophage phagocytosis and microbicidal function to a greater extent compared with propofol. Halothane, isoflurane, and enflurane attenuate free radical–mediated myocardial injury. Isoflurane and halothane (but not sevoflurane) appear to attenuate hydroxy radical production in the ischemic rat heart. Sevoflurane and isoflurane and halothane reduce neutrophil and platelet uptake in the coronary circulation and preserve cardiac function following myocardial ischemia and reperfusion. This effect is mediated at least in part via reduced neutrophil expression of the adhesion molecule CD11b.  

Clonidine appears to exert antiinflammatory actions in such diverse areas as acute pain models, in extrinsic asthma, and angiotensin-converting enzyme inhibitor–induced inflammation. It appears that the antiinflammatory action of clonidine is a property of α2 adrenergic receptor activation. Furthermore, α2 adrenoceptor agonists may regulate cytokine production via stimulation of α2 receptors on macrophages to augment TNF-α release in response to endotoxin. While use of clonidine during CABG does not appear to influence the perioperative stress response, its immunomodulatory effects in the context of CPB remain to be characterized.

Surgical Factors

Proinflammatory cytokine concentrations in patients undergoing heart transplantation are greater than in CABG patients. Possible explanations include the fact that these patients have severe ventricular dysfunction, a condition known to increase cytokine concentrations after cardiac surgery, or to the longer ischemia time required to perform this procedure. The later course of cytokine concentrations after heart transplantation may be further influenced by immunosuppressive therapy. Patients undergoing valve surgery appear to have similar immunologic response profiles to CABG patients. In general, indices of inflammation appear to correlate with overall severity of illness rather than specific surgical procedure.  

Extracorporeal Perfusion Factors

The composition of the priming solution, cardioplegia, presence of pulsatile or nonpulsatile perfusion, type of oxygenator and pump, type of extracorporeal circuit, and temperature during CPB are all important factors influencing the inflammatory response. In an isolated circuit, CPB duration correlated with IL-8 concentrations and neutrophil adhesion molecule expression. The release of inflammatory mediators appears to be temperature dependent, with warm CPB associated with an increased inflammatory response compared to hypothermic CPB. However, there is evidence to suggest that hypothermic CPB may simply delay cytokine release and neutrophil activation, and that tepid CPB, in which the core temperature is simply allowed to drift to 32–34°C, may most effectively attenuate the inflammatory response. Warm blood cardioplegia reduces the inflammatory response as compared to cold crystalloid cardioplegia. Heparin-coated CPB circuits reduce complement and proinflammatory cytokite release. The type of CPB prime, i.e., colloid (gelofusine) versus crystalloid, does not appear to influence cytokine release. Membrane oxygenators may result in less activation of the inflammatory system and improve postoperative cardiac, respiratory, and renal function. However, a later study demonstrated no sustained advantage over bubble oxygenators in terms of inflammatory activation or postoperative respiratory function. In pediatric patients undergoing CPB, use of centrifugal pumps may result in less activation of the inflammatory response, however, another study demonstrated no advantage over conventional roller pumps. In adult
CPB patients, centrifugal pumps may induce a greater inflammatory response than roller pumps. Pulsatile CPB flow is associated with less endotoxemia, lower cytokine and endothelin-1 concentrations, and increased NO production.

Shear Stress. During normal circulation within the vasculature, blood is exposed to various physical or mechanical forces. This is termed “shear stress” and may have a physiologic function, such as releasing NO from the endothelium. However, excessive shear stress may develop during CPB as a result of large pressure changes across the CPB circuit, causing damage to blood constituents and activating the inflammatory response. Shear stress appears to be especially pronounced along the arterial cannula. Shear stress decreases erythrocyte deformability and increases hemolysis. Leukocyte adhesiveness is increased, and mechanical disruption, with neutrophil degranulation and release of cytotoxic products, may be seen at high levels of shear stress. Excess shear stress also increases platelet activation and may contribute to endothelial injury. Strategies that minimize shear stress, by decreasing the pressure decrease across the CPB circuit, such as the use of hollow fiber membrane oxygenators, reduce leukocyte activation.

Transfusion

Allogeneic Transfusion. An estimated 20% of allogeneic blood transfusions in the United States are associated with cardiac surgery. The immunomodulatory effects of allogeneic transfusion in cardiac surgical patients are increasingly recognized. Allogeneic blood transfusions appear to exacerbate the proinflammatory response to cardiac surgery. Intraoperative packed erythrocyte transfusions directly increase the concentrations of inflammatory mediators and indirectly stimulate the inflammatory response. This may explain, in part, the greater morbidity in patients who receive intraoperative allogeneic packed cells. In addition, transfusion-associated graft-versus-host disease is a recognized complication of fresh nonirradiated homologous whole blood.

Allogeneic erythrocytes are usually given to augment systemic oxygen delivery. However, a controlled clinical trial failed to demonstrate a beneficial effect of erythrocyte transfusion on systemic oxygen uptake in critically ill patients with sepsis. In fact, patients receiving old transfused erythrocytes developed evidence of splanchnic ischemia. The investigators postulated that the poorly deformable transfused erythrocytes cause microcirculatory occlusion and tissue ischemia in some organs. These concerns have been further highlighted by a recent large multicenter study of critically ill intensive care unit (ICU) patients that demonstrated that a restrictive strategy of erythrocyte transfusion improved mortality in the less severely ill patients and overall was at least as effective as and possibly superior to a liberal transfusion strategy.

Autotransfusion. Autotransfusion of shed blood from the thoracic cavities during and following CPB is a common clinical practice used to reduce the need for allogeneic blood transfusion. However, concerns exist regarding the efficacy and safety of autotransfusion. Extensive clotting and fibrinolysis have been demonstrated in blood from the thoracic cavities during CPB. Studies to date on the efficacy of autotransfusion in reducing allogeneic blood transfusion have yielded conflicting results. One recent randomized clinical trial demonstrated that autotransfusion reduced allogeneic transfusion requirements but led to increased postoperative bleeding. Conversely, in another randomized controlled trial, autotransfusion of blood suctioned from the thoracic cavity during the surgical procedure increased circulating concentrations of thrombin-antithrombin III complex, tissue-type plasminogen activator, fibrin degradation products, and free plasma hemoglobin. Autotransfusion impaired hemostasis, resulting in increased postoperative blood loss and similar if not increased consumption of blood products when compared to patients who were not autotransfused. A metaanalysis of randomized trials assessing the effectiveness of cell salvage to minimize perioperative allogeneic blood transfusion in cardiac surgical patients concluded that it was only of marginal benefit. Of further concern, the potential exists for autotransfused blood to stimulate the inflammatory response. Shed mediastinal blood contains a high proportion of activated leukocytes with a significantly increased production of TNF-α and IL-6 seen in vitro studies. However, in one study, while shed mediastinal blood did contain high concentrations of IL-6 and activated leukocytes, autotransfusion in the postoperative period did not cause measurable elevations in cytokines.

Postoperative Factors

Continuous Renal Replacement Therapies. Continuous renal replacement therapies such as hemofiltration appear to remove both mediators, including TNF-α and IL-1β, and their inhibitors, such as TNFsr1, TNFsr2, and IL-1ra, from the plasma of patients with SIRS. This offers the possibility that these therapies may alter the course of SIRS in critically ill patients. However, the use of continuous renal replacement therapy in the absence of conventional indications for dialytic support remains unproven. No significant survival advantage has been demonstrated for critically ill patients with SIRS-MODS when treated with continuous renal replacement therapy as an adjunct to conventional therapy.

Mechanical Ventilation. Ventilatory strategies involving stretch of unrecruited lung units (i.e., high tidal volume, low positive end-expiratory pressure), appear to cause—or potentiate—ALI. Furthermore, such injury
may contribute to the inflammatory response by several mechanisms, such as facilitating translocation of intrapulmonary bacteria across the alveolar capillary barrier, \(^2\) accumulation of intrapulmonary cytokines, \(^3\) and release of cytokines into the systemic circulation. \(^4\) The role of ventilatory strategies in the inflammatory response following CPB is not yet known. However, in patients with acute respiratory distress syndrome, ventilation strategies that minimize overdistention and recruitment–derecruitment of the lung attenuate the inflammatory response. \(^5\)

Clinical Implications of the Inflammatory Response to Cardiac Surgery

**Potential Beneficial Effects**

A controlled, self-limiting inflammatory response to cardiac surgery has important beneficial effects such as immune system priming, which may aid in preventing perioperative infection and promoting wound healing (fig. 5). CPB priming of neutrophils may be beneficial in preparing the host to mount a robust response to the physiologic stresses of the perioperative period. In this context, experimental pretreatment with inhaled endotoxin induces pulmonary leukocyte recruitment, which protects against subsequent bacterial lung infections. \(^6\) Gut translocation of endotoxin in minute amounts may be a physiologically important phenomenon to boost the reticuloendothelial system, especially Kupffer cells. \(^7\) TNF-α and IL-1β have been shown to be necessary for wound healing, \(^8\) and TNF-α may even function to downregulate certain aspects of the inflammatory response. \(^9\) Finally, IL-1β pretreatment may reduce the severity of ischemia and reperfusion injury. \(^10\)
**Potential Adverse Effects**

An uncontrolled inflammatory response appears to play a significant role in the morbidity or mortality observed in patients undergoing CPB (fig. 5). The inflammatory response contributes to the pathogenesis of acute pulmonary, cardiovascular, neurologic, splanchnic, hematologic, and immune system dysfunction following cardiac surgery. In addition, although less well documented, there is evidence to suggest that the inflammatory response contributes to the pathogenesis of subacute sequelae, such as postoperative fever, postcardiotomy pericarditis, and pleural effusions after CPB.

**Pulmonary.** Acute lung injury, defined as the triad of hypoxemia (PaO_2_/FiO_2_ ≥ 300), bilateral pulmonary infiltrates, and normal pulmonary capillary wedge pressure, is a serious and poorly understood complication following cardiac surgery. The risk and severity of ALI has been consistently linked to duration of CPB. Other issues related to CPB, such as the type of oxygenator used, may also contribute to the risk of ALI.

Severe ALI following CPB, while relatively uncommon (1–3%), has been associated with a 50% mortality. Lesser degrees of lung injury, such as reduced oxygenation index, increased V/Q mismatch, decreased lung compliance, are seen in up to 12% of patients. Pulmonary injury is detectable even following uncomplicated CPB using sensitive measures of ALI, such as protein accumulation index and bronchoalveolar lavage neutrophil and myeloperoxidase concentrations. Early pulmonary dysfunction after cardiac surgery increases morbidity, including renal, neurologic, and infectious complications, duration of mechanical ventilation, ICU and hospital stays, and risk of mortality.

The inflammatory response has deleterious effects on the pulmonary circulation and the lung parenchyma. Several lines of evidence implicate the inflammatory response in the pathogenesis of postoperative pulmonary dysfunction. Histologic evidence demonstrates that CPB can cause profound pulmonary endothelial, epithelial, and interstitial damage. Up to 50% of circulating neutrophils are sequestered in pulmonary capillaries during rewarming, with subsequent degranulation contributing to pulmonary vascular endothelial damage. Postoperative elevations of granulocyte elastase, an index of neutrophil lysosomal degranulation, correlate with deterioration in the oxygenation index, alveolar-arterial gradient, and intrapulmonary shunt. Increases in pulmonary vascular permeability following CPB correlate with markers of lipid peroxidation and a reduction of plasma antioxidants, both indicators of an oxygen-radical–induced injury process.

Strategies that attenuate the inflammatory response may reduce post-CPB ALI. While serum and alveolar proinflammatory mediator concentrations correlate with post-CPB pulmonary dysfunction, mechanical mediator removal may decrease lung injury. Leukocyte depletion during CPB, or blockade of neutrophil adhesion, attenuates postoperative lung dysfunction. Finally, inhibition of complement activation results in significant reduction of post-CPB ALI.

**Cardiovascular.** Major perioperative cardiovascular complications (cardiac death, myocardial infarction, heart failure) occur in at least 10% of CABG patients. The Multicenter Study of Perioperative Ischemia Research Group, in a multicenter study involving 566 patients after CABG, found that up to 25% fulfilled either electrocardiogram (i.e., presence of Q waves), CK-MB fraction, or autopsy criteria for myocardial infarction. Nearly 10% of patients had a Q-wave infarct, while 20.5% fulfilled CK-MB criteria for myocardial infarction.

The inflammatory response may be involved in the pathogenesis of post-CPB cardiovascular dysfunction. Increased hemodynamic instability during cardiac surgery may result from systemic spillover of proinflammatory cytokines, such as IL-6. Furthermore, there appears to be a clear link between CPB-induced inflammatory mediators and postbypass myocardial stunning, ischemia, and dysfunction, and β-adrenergic desensitization.

TNF-α, IL-1β, and IL-6 have been implicated in cardiac myocyte refractoriness to adrenergic stimulation following CPB. Myocardial performance in elderly patients after CPB is suppressed by TNF-α, while anti-TNF antibodies reverse the myocardial depression seen in sepsis. Left ventricular wall motion abnormalities and myocardial ischemic episodes after CPB correlate with IL-6 or IL-8 concentrations.

Alterations in NO homeostasis may play an important role in the pathogenesis of cardiovascular events following cardiac surgery. The human myocardium constitutively produces NO via eNOS, and this is regulated by the contractile state of the heart, possibly by a β-adrenergic signaling pathway. This constitutively produced NO has important cardioprotective effects, including regulation of vascular tone, myocyte refractoriness to adrenergic stimulation, myocardial contractility, coagulation, and pulmonary endothelial function. However, up-regulation of iNOS by proinflammatory cytokines following CPB may greatly increase myocardial NO production. In this context, NO may have deleterious effects and contribute to postoperative myocardial dysfunction, particularly myocardial stunning. IL-1β up-regulates iNOS-mediated NO production and has been demonstrated to depress myocardial contractility through a NO-dependent mechanism. Mechanisms underlying NO-mediated myocardial dysfunction may include inhibition of mitochondrial activity, induction of adrenergic refractoriness, increased platelet adhesiveness, and peroxynitrite-induced cellular damage.

**Neurologic.** Neurologic complications increase perioperative morbidity following cardiac surgery, resulting in longer hospitalization, and may increase mortality up
to 10-fold.13 Focal cerebral deficits, such as transient ischemic attacks and stroke, occur in 1–3% of patients, while less severe clinical abnormalities, such as seizures, are observed in 5–10%.244 Postoperative neurologic dysfunction, including cognitive dysfunction and disability, unrelated to focal injury, is seen in 69% of patients immediately postoperatively and persists for at least 1 month in 36%.246 Patients with the apolipoprotein E-ε4 allele247 or previous neurologic injury248 may be predisposed to neurologic complications after CPB. In the largest series to date, the mortality rate was 29% in patients with adverse cerebral complications.245

The inflammatory response plays a pivotal role in the pathogenesis of post-CPB neurologic injury. The role of endothelial dysfunction and the endothelial–neutrophil interaction in neurologic injury after CPB is well documented. Loss of cerebrovascular endothelial-mediated vasodilation may contribute to the pathogenesis of postoperative perfusion deficits.249 NO formed by up-regulation of neuronal NOS, e.g., in response to glutamate, has been implicated as a potent neurotoxin in animal models of post-CPB neurologic injury.250,251

Strategies that attenuate the inflammatory response may decrease neurologic injury. Experimental blockade of selectin adhesion molecules reduces cerebral injury in an animal model.252 Aprotinin, a serine protease inhibitor with important hemostatic and antiinflammatory properties, decreases the incidence of stroke after CPB.253 Finally, heparin coating of CPB circuits, which improves its biocompatibility, thereby reducing contact activation of the inflammatory response, may reduce the incidence of neurologic dysfunction in humans.254

**Renal.** Perioperative renal dysfunction occurs in 7–13% of patients, with 1–1.5% requiring some form of dialytic therapy.18,255 Renal insufficiency following cardiac surgery increases ICU and hospital stay and greatly increases mortality (27% vs. 0.9%).18 The mortality rate for patients requiring postoperative dialysis ranges from 28–64%.18,255 The incidence of renal dysfunction is directly related to the duration of CPB.18

The role of the inflammatory response in the pathogenesis of renal dysfunction continues to be defined. Renal ischemia–reperfusion injury combined with the inflammatory response to CPB may be important causes of renal dysfunction after CPB. Hypoperfusion of the superficial renal cortex has been demonstrated during the rewarming phase of CPB in an animal model.256 The inflammatory response may exacerbate renal hypoperfusion, both indirectly as a result of hemodynamic instability, and directly via renal arteriolar vasoconstriction and altered intrarenal distribution of perfusion due to alterations in catecholamines and NO concentrations. TNF-α released during CPB induces glomerular fibrin deposition, cellular infiltration, renal cell apoptosis, and vasoconstriction, leading to a reduction in the glomerular filtration rate.17 Furthermore, anti-TNF-α strategies have been proposed to reduce renal insufficiency after CPB.17

**Hepatic.** Hepatic dysfunction following CPB is common, with up to 47% of patients developing at least transient postoperative dysfunction.257 Postoperative hepatic dysfunction is related to the duration of CPB and may greatly increase mortality.258

The mechanism of hepatic injury after CPB and the role of the inflammatory response is not well characterized. Nevertheless, there is some evidence that the inflammatory response to CPB may play a role in hepatic injury. Hepatic ischemia–reperfusion injury may result from hepatic venous congestion during weaning from CPB.19 High concentrations of C3a and C4a have been associated with post-CPB liver dysfunction in humans.257 During hypothermic bypass, portal concentrations of endothelin-1, a potent vasoconstrictor, have been associated with decreased hepatic blood flow and post-CPB liver dysfunction in an animal model.259 In patients following CPB, hepatic perfusion may be decreased for up to 24 h.22 Finally, there is increasing evidence that cytokines TNF-α and IL-6 may contribute to the pathogenesis of hepatocellular dysfunction.260

**Hemostatic.** Cardiopulmonary bypass–induced hemostatic defects may contribute significantly to perioperative morbidity. Potential mechanisms include direct contact activation of the coagulation and fibrinolytic cascades by the bypass circuit, platelet dysfunction, and capillary leak due to endothelial damage. The inflammatory response may be central to the development of these hemostatic defects. The amount of postoperative blood loss has been correlated with degree of activation of the complement cascade.261 Mechanical removal of cytokines, such as by hemofiltration, has been associated with a reduction in postoperative blood loss following cardiac surgery.56

Cardiopulmonary bypass–associated impairment of platelet function may be cytokine mediated.262 Endotoxin and IL-1β stimulate the release of von Willebrand factor from the vascular endothelium, which may promote activation and localization of platelets and enhance thrombogenicity at inflammatory foci.263 Platelet activation during CPB may contribute, through IL-1β release, to endothelial cell activation.262 Preoperative harvest of platelet-rich plasma with reinfusion following CPB may result in significantly less pulmonary dysfunction and shorter ICU stays, in addition to improved hemostatic function.254 In addition, nonsurgical postoperative bleeding is correlated with both leukocyte count and the percentage change in leukocyte count over the course of CPB.265 Finally, CPB with more biocompatible circuits may decrease platelet activation, fibrinolysis, and thrombin generation and increase platelet preservation.266

**Immunosuppression.** Cardiopulmonary bypass–associated immunosuppression may play an important role in the development of postoperative infectious compli-
cations. Immunosuppression may result from a predominance of antiinflammatory cytokine production. Cell-mediated immunity is also altered with decreases in CD3+ T-lymphocyte and CD4+ T-helper cell counts, increases in CD8+ suppressor–cytotoxic T cells and monocyte counts, decreased lymphocyte responsiveness to mitogens, and suppression of the T-helper cell–induced cell-mediated inflammatory response after CPB. Pretreatment with indomethacin and thymopentin, which stimulates activation and differentiation of the T-lymphocytes, appears to restore certain aspects of this response. IL-10 may play a role in postoperative immunosuppression, with IL-10 gene expression correlating with decreased monocyte HLA-DR antigen expression in a study of patients undergoing major abdominal surgery. These alterations in the inflammatory response highlight the need to consider both the potential beneficial and adverse aspects of this response and further underline the clinical benefit of a balanced, controlled inflammatory response to CPB.

Therapeutic Strategies to Modulate the Inflammatory Response

The development of strategies to control the inflammatory response following cardiac surgery is currently the focus of considerable research efforts. Diverse techniques, including maintenance of hemodynamic stability, minimization of exposure to CPB circuitry, and pharmacologic and immunomodulatory agents have been examined in clinical studies. Table 5 summarizes the findings of recent randomized clinical trials in this field.

Risk Stratification

Accurate risk stratification would permit selective delivery of potentially useful therapies to those patients who might be expected to derive most benefit. Clinical risk assessment has taken the form of complex multivariate modelling. An approach that combines assessment of “fixed” baseline risk together with “dynamic” event-related risk related to adverse perioperative events probably holds most promise (fig. 6). In this regard, several key indices of the inflammatory response appear to predict postoperative morbidity following cardiac surgery and may help to further stratify patient risk. In the preoperative phase, elevation of C-reactive protein concentrations predicts a greater likelihood of septic complications and need for catecholamine therapy, longer duration of respiratory support, and increased duration of ICU stay, while low preoperative immunoglobulin M antiendotoxin core antibody concentrations independently predict poor postoperative outcome. Postoperatively, early elevations in serum soluble TNF receptor-p55 concentrations in high-risk cardiac surgical patients predicts increased mortality. Finally, the characterization of particular genotypes, such as apolipoprotein E-ε 4 allele, which predicts risk of post-CPB neurologic injury, is a novel approach that holds promise.

**Novel Cardiac Surgical Techniques**

**Off-pump Coronary Artery Bypass Grafting.** Concerns regarding complications and cost surrounding the use of CPB has led to renewed interest in off-pump coronary artery bypass grafting (OPCAB) techniques. Extensive observational data suggest a relation between poor outcome and the use of (1) aortic cross-clamping and concomitant global ischemia and reperfusion injury and (2) extracorporeal circulation. Avoidance of aortic cross-clamping and CPB may decrease the inflammatory response and improve postoperative organ function and patient outcome, particularly in high-risk patients.

Off-pump coronary artery bypass grafting does reduce the elaboration of key mediators of the systemic inflammatory response. OPCAB decreases concentrations of cytokines such as TNF-α, IL-6, IL-8, IL-10, and TNFα1 and 2. OPCAB attenuates the cellular inflammatory response, decreasing neutrophil and monocyte counts, neutrophil elastase, and E-selectin concentrations. Indices of complement activation, such as C3a and C5a, are decreased. In addition, OPCAB attenuates other indices, including platelet β-thromboglobulin and procalcitonin. Finally, OPCAB decreases reactive oxygen species-induced injury.

The clinical trials reported to date suggest that OPCAB may attenuate indices of postoperative organ dysfunction but does not eliminate SIRS following cardiac surgery (table 5). Initial clinical experience with selected patients suggests reduced cardiovascular, pulmonary, neurologic, and hemostatic dysfunction, with decreased morbidity and shorter ICU and hospital stay. One retrospective study comparing elderly patients undergoing OPCAB to matched conventional controls indicated that OPCAB decreased postoperative cardiovascular complications and expedited ICU and hospital discharge. However, these trials were small, with enrollment restricted to low-risk patients, often with specific single or double vessel coronary lesions. There are no reported randomized trials of OPCAB in high-risk patients. A retrospective comparison of the first 55 patients who underwent OPCAB at Duke University Medical Center to a larger cohort who underwent conventional CABG failed to demonstrate a reduction in renal risk. Therefore, the short-term benefits of OPCAB remain to be convincingly demonstrated.

**Minimally Invasive Cardiac Surgery.** Advances in minimally invasive surgery in other areas, such as laparoscopic and thoracoscopic procedures, have prompted interest in approaches that avoid full median sternotomy. Minimally invasive cardiac surgery techniques

Anesthesiology, V 97, No 1, Jul 2002
<table>
<thead>
<tr>
<th>Study</th>
<th>Intervention (n per group)</th>
<th>Main Results</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Novel CABG techniques</strong>&lt;br&gt;Ascione et al., 283 2000</td>
<td>CAGB with CPB (30) versus off-pump CAGB (30) in low-risk patients</td>
<td>Off-pump CAGB group had shorter intubation time and length of ICU and hospital stay, lower incidence of postoperative total and pulmonary infection, and lower blood loss and transfusion requirements.</td>
</tr>
<tr>
<td>Cox et al., 284 2000</td>
<td>CAGB with CPB (26) versus off-pump CAGB (26) in low-risk patients</td>
<td>Off-pump group had decreased total postoperative respiratory complications [combined chest infection, pneumothorax, lung collapse] and reduced postoperative blood loss. No intergroup difference in degree of pulmonary dysfunction, as assessed by alveolar-arterial oxygen gradient.</td>
</tr>
<tr>
<td>Matata et al., 278 2000</td>
<td>CAGB with CPB (10) versus off-pump CAGB (10) in low-risk patients with single or double vessel disease</td>
<td>Off-pump CAGB group had shorter duration of mechanical ventilation, less postoperative blood loss, less postoperative fever. No intergroup difference in length of hospital stay.</td>
</tr>
<tr>
<td>Richter et al., 291 2000</td>
<td>CAGB with full CPB (15) versus CAGB (15) using lungs as oxygenator in low-risk patients</td>
<td>Lung oxygenator group had decreased pulmonary [Pao2, A-aO2 gradient, intrapulmonary shunt, respiratory index] and hemostatic [postoperative blood loss, allogenic blood transfusion] dysfunction.</td>
</tr>
<tr>
<td>Ascione et al., 278 1999</td>
<td>CAGB with CPB (25) versus off-pump CAGB (25) in low-risk patients</td>
<td>Off-pump CAGB group had improved maintenance of renal function [creatinine clearance; urinary microalbumin/creatinine ratio; N-acetyl glucosaminidase activity]; decreased blood loss; decreased blood, platelet, and plasma transfusion; decreased ICU and hospital stay.</td>
</tr>
<tr>
<td>Gu et al., 281 1998</td>
<td>CAGB with CPB (31) versus off-pump CAGB (31) in low-risk patients with isolated LAD stenosis</td>
<td>Off-pump group had shorter duration of surgical procedure, less blood, shorter ventilatory support, and a shorter postoperative hospital stay.</td>
</tr>
<tr>
<td><strong>Thoracic epidural anesthesia</strong>&lt;br&gt;Loick et al., 151 1999</td>
<td>Thoracic epidural anesthesia (25) versus clonidine (24) versus control [no intervention] (21) in low-risk CAGB patients</td>
<td>Thoracic epidural anesthesia group had decreased myocardial injury [lower troponin T]; decreased myocardial ischemia [ST-segment changes]; decreased stress response [plasma epinephrine]; and decreased pulmonary injury [decreased duration of tracheal intubation].</td>
</tr>
<tr>
<td><strong>CPB temperature</strong>&lt;br&gt;Ohata et al., 274 1997</td>
<td>CPB at 34°C (10) versus CPB at 34°C (8) in low-risk CAGB patients</td>
<td>Tepid CPB [34°C] group had decreased pulmonary injury [lower respiratory index; decreased duration of tracheal intubation].</td>
</tr>
<tr>
<td><strong>Heparin-coated circuits</strong>&lt;br&gt;Belboul et al., 295 2000</td>
<td>HCCs (20) versus conventional circuits (19) in low-risk CAGB patients</td>
<td>HCC group had decreased myocardial injury [CK-MB concentrations]; decreased plasma hemoglobin. No intergroup difference in postoperative blood loss, duration of mechanical ventilation, ICU or hospital stay.</td>
</tr>
<tr>
<td>Grossi et al., 432 2000</td>
<td>HCCs (11) versus conventional circuits (12) in pediatric patients</td>
<td>HCC group had improved pulmonary [lower postoperative peak airway pressure] and coagulation [prothrombin time] function.</td>
</tr>
<tr>
<td>Ranucci et al., 49 1999</td>
<td>Duraflo II HCCs (442) versus conventional circuits (444) in medium- to high-risk patients</td>
<td>HCC group had shorter length of ICU and hospital stay, lower rate of postoperative morbidity or death. No intergroup difference in duration of mechanical ventilation. Subgroup analysis showed less renal dysfunction in diabetic patients, and less lung dysfunction in patients with COPD or postmortal valve procedure.</td>
</tr>
</tbody>
</table>

CABG = coronary artery bypass grafting; CPB = cardiopulmonary bypass; ICU = intensive care unit; Pao2 = arterial oxygen tension; A-aO2 gradient = alveolar-arterial gradient for oxygen; LAD = left anterior descending artery; HCC = heparin-coated circuit; CK-MB = creatine kinase myocardial isozyme; COPD = chronic obstructive pulmonary disease; IABP = intraaortic balloon pump; pH = gastric intramucosal pH; SvO2 = mixed venous oxygen saturation; CO = cardiac output; GIT = gastrointestinal tract; AVR = aortic valve replacement; MVR = mitral valve replacement; CI = cardiac index; LVEF = left ventricular ejection fraction; HR = heart rate; MAP = mean arterial pressure; Hb = hemoglobin; PCWP = pulmonary capillary wedge pressure; CNS = central nervous system; MI = myocardial infarction; APACHE = Acute Physiology and Chronic Health Evaluation; NAC = N-acetyl cysteine; SVRI = Systemic Vascular Resistance Index; PIP = peak inspiratory pressure; IL = interleukin.

Anesthesiology, V 97, No 1, Jul 2002
### Table 5. (continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>Intervention (n per group)</th>
<th>Main Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shimamoto &lt;et al.,&lt;sup&gt;299&lt;/sup&gt; 2000</td>
<td>Group A (10), HCC with silicone-coated oxygenator; group B (11), whole HCC; group C (11), conventional circuit; in low-risk patients</td>
<td>Group A: A-a&lt;sub&gt;O&lt;/sub&gt; gradients and respiratory index better than control. Group B: A-a&lt;sub&gt;O&lt;/sub&gt; gradient was better than control. Duration of intubation and the length of ICU stay shorter in groups A and B than in group C. Silicone-coated oxygenator superior to heparin-coated oxygenator.</td>
</tr>
<tr>
<td>Wan et al.,&lt;sup&gt;300&lt;/sup&gt; 1999</td>
<td>Duraflo II HCCs (14) versus conventional circuits (15) in patients undergoing heart or heart–lung transplants</td>
<td>HCC group had less myocardial injury [cardiac troponin I]. No intergroup difference in postoperative blood loss and transfusion, duration of mechanical ventilation, length of ICU stay, or mortality.</td>
</tr>
<tr>
<td>Videm et al.,&lt;sup&gt;298&lt;/sup&gt; 1999</td>
<td>Duraflo II HCCs (81) versus conventional circuits (75) in high-risk patients</td>
<td>No intergroup difference in postoperative blood loss, duration of mechanical ventilation, organ dysfunction, infection or reoperation rates, or mortality.</td>
</tr>
<tr>
<td>Wildevuur et al.,&lt;sup&gt;297&lt;/sup&gt; 1997</td>
<td>Duraflo II HCCs (398) versus conventional circuits (407) in low-risk CABG patients</td>
<td>Wide variability among study centers. No intergroup difference in postoperative: blood loss, transfusion requirements; myocardial infarction; neurologic, respiratory, renal or hepatic dysfunction; ICU stay; morbidity or mortality. On analysis of subgroups with higher morbidity, HCC was beneficial in females [lower blood product use, earlier tracheal extubation, fewer arrhythmias] and patients with long aortic cross-clamp time [shorter ICU stay; trend to less IAPB use].</td>
</tr>
<tr>
<td>Jansen et al.,&lt;sup&gt;254&lt;/sup&gt; 1996</td>
<td>HCCs (51) versus conventional circuits (51) with aprotinin prime in low-risk patients receiving aspirin</td>
<td>HCC group had shorter ICU stay and lower overall risk for adverse events [combined incidence cardiac, coagulation, respiratory, neurologic dysfunction]. No intergroup difference in postoperative blood loss, transfusion requirements, vasoactive medication support, or duration of endotracheal intubation.</td>
</tr>
</tbody>
</table>

#### Selective digestive decontamination

<table>
<thead>
<tr>
<th>Study</th>
<th>Intervention (n per group)</th>
<th>Main Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nathens et al.,&lt;sup&gt;308&lt;/sup&gt; 1999</td>
<td>Meta-analysis of SDD, subanalysis of SDD in low-risk cardiac surgical patients</td>
<td>SDD in cardiac surgical patients reduced incidence of infection but did not alter mortality in a group of patients with low baseline mortality rate.</td>
</tr>
<tr>
<td>Martinez-Pellus et al.,&lt;sup&gt;23&lt;/sup&gt; 1997</td>
<td>SDD (50) versus control (50) in low-risk patients</td>
<td>SDD group had attenuation of the decrease in gastric pH. No change in rate of fever, respiratory or coagulation dysfunction, sepsis-like syndrome, or duration of ICU stay.</td>
</tr>
</tbody>
</table>

#### Hemodynamic optimization

<table>
<thead>
<tr>
<th>Study</th>
<th>Intervention (n per group)</th>
<th>Main Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pöllönen et al.,&lt;sup&gt;321&lt;/sup&gt; 2000</td>
<td>Hemodynamic goal-directed therapy (196) [maintain S&lt;sub&gt;vo&lt;/sub&gt;&lt;sub&gt;2&lt;/sub&gt; &gt; 70%; lactate ≥ 2.0 mm] versus conventional therapy (197)</td>
<td>Similar intergroup length of ICU stay. Median hospital stay was shorter and incidence of organ dysfunction was lower in the protocol group. Trend to reduced mortality in protocol group.</td>
</tr>
<tr>
<td>Christenson et al.,&lt;sup&gt;327&lt;/sup&gt; 1999</td>
<td>Preoperative IABP (30) versus conventional therapy (30) in high-risk CABG patients, preoperative IABP subgroups: 2 h (10), 12 h (10), and 24 h (10) prior to aortic cross-clamp</td>
<td>Preoperative IABP group had lower incidence of postoperative low CO; shorter intubation time and length of ICU and hospital stay. Trend toward lower mortality in IABP group. There were no differences between the IABP subgroups, with 2 h counterpulsation equally effective. The overall IABP complication rate was 8.3%.</td>
</tr>
<tr>
<td>Mollhoff et al.,&lt;sup&gt;24&lt;/sup&gt; 1999</td>
<td>Milrinone [30 μg/kg bolus; 0.5 μg · kg⁻¹ · min⁻¹] (11) versus placebo (11) in low-risk CABG patients</td>
<td>Milrinone attenuated the decrease in splanchnic oxygenation [gastric pH] and preserved gut barrier function [hepatic venous endotoxin] but had no effect on renal function [creatinine clearance].</td>
</tr>
<tr>
<td>Berendes et al.,&lt;sup&gt;325&lt;/sup&gt; 1997</td>
<td>Dopexamine 0.5 (10), 1.0 (10), or 2 μg · kg⁻¹ · min⁻¹ (10) versus placebo (14) in low-risk CABG patients</td>
<td>Dopexamine preserved renal function [creatinine clearance]; but had no effect on splanchnic oxygenation [gastric pH, hepatic venous oxygen saturation] or pulmonary function [shunt fraction].</td>
</tr>
<tr>
<td>Loick et al.,&lt;sup&gt;433&lt;/sup&gt; 1997</td>
<td>Enoximone [0.2-mg/kg bolus; 5 μg · kg⁻¹ · min⁻¹] (10) versus placebo (11) in low-risk CABG patients</td>
<td>Enoximone preserved gut barrier function [hepatic venous endotoxin] but had no effect on splanchnic oxygenation [gastric pH].</td>
</tr>
<tr>
<td>Sinclair et al.,&lt;sup&gt;326&lt;/sup&gt; 1997</td>
<td>Dopexamine [2.0 μg · kg⁻¹ · min⁻¹] (14) versus Dopamine [2.5 μg · kg⁻¹ · min⁻¹] (16) in low-risk CPB patients</td>
<td>Dopexamine reduced GIT permeability versus dopamine following CPB. No intergroup difference in pH.</td>
</tr>
</tbody>
</table>
Table 5. (continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>Intervention (n per group)</th>
<th>Main Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mythen et al., 1995</td>
<td>Perioperative plasma volume expansion protocol (30) versus conventional therapy (30) in low-risk patients [CABG, AVR, MVR]</td>
<td>Plasma volume expansion with colloid reduced the incidence of splanchnic dysoxia [gastric pH], reduced ICU and hospital stay, and decreased major complication rate [single or multiple organ dysfunction].</td>
</tr>
<tr>
<td>Parviainen et al., 1999</td>
<td>Dobutamine [3.5–5.5 μg · kg⁻¹ · min⁻¹] (11) versus placebo (11) in postoperative CABG patients with CI &gt; 2 l · min⁻¹ · m⁻²</td>
<td>Dobutamine decreased splanchnic oxygenation [gastric pH].</td>
</tr>
<tr>
<td>Hemofiltration</td>
<td>Modified hemofiltration (20) versus control [no intervention] (20) in low-risk adults for CABG</td>
<td>In the hemofiltered group cardiac output, cardiac index, and systemic vascular resistance values were significantly greater in the early postoperative period only. Hemofiltered group required less allogeneic blood postoperatively. No mortality or organ dysfunction in either group.</td>
</tr>
<tr>
<td>Bando et al., 1998</td>
<td>Dilutional ultrafiltration during CPB and venovenous modified ultrafiltration after CPB (50) versus control group (50) during CPB in pediatric patients with complex congenital heart disease</td>
<td>Overall, modified ultrafiltration attenuated pulmonary [reduced duration of ventilatory support] and coagulation [decreased blood and coagulation factor transfusion] dysfunction, and decreased ICU stay. Preoperative pulmonary hypertension: modified ultrafiltration reduced postoperative pulmonary arterial pressure, attenuated pulmonary [PaO₂, reduced duration of ventilatory support] coagulation [decreased postoperative blood loss and blood and coagulation factor transfusion] dysfunction; led to earlier chest tube removal; and decreased ICU stay. Neonates: Modified ultrafiltration attenuated pulmonary [reduced duration ventilatory support] and coagulation [decreased coagulation factor transfusion] dysfunction; and decreased ICU stay. Prolonged CPB: Modified ultrafiltration attenuated pulmonary [reduced duration ventilatory support] and coagulation [decreased blood and coagulation factor transfusion] dysfunction; and decreased ICU stay.</td>
</tr>
<tr>
<td>Bando et al., 1998</td>
<td>Dilutional and modified ultrafiltration (12) versus conventional ultrafiltration (12) in pediatric patients with pulmonary hypertension at end of CPB</td>
<td>Dilutional and modified ultrafiltration group decreased pulmonary [PaO₂, duration of ventilatory support] and coagulation [less requirements for platelets and fresh frozen plasma] dysfunction; decreased pulmonary/systemic pressure ratio; and tended toward less pulmonary hypertensive crises.</td>
</tr>
<tr>
<td>Davies et al., 1998</td>
<td>Modified ultrafiltration (MUF) (11) versus control [no intervention] (10) in infants at end of CPB</td>
<td>Modified ultrafiltration improved intrinsic left ventricular systolic function, improved diastolic compliance, increased blood pressure, and decreased inotrope use in the early postoperative period. However, no intergroup difference in mortality, duration of ventilatory support, or ICU stay.</td>
</tr>
<tr>
<td>Babka et al., 1997</td>
<td>Conventional ultrafiltration (30) versus control [no intervention] (30) in adults for CABG</td>
<td>No intergroup difference in postoperative blood loss, blood transfusion requirements, length of hospital stay, or patient cost.</td>
</tr>
<tr>
<td>Journois et al., 1996</td>
<td>High volume, zero balanced hemofiltration (10) versus standard hemofiltration (10) in pediatric patients at end of CPB</td>
<td>High volume, zero balanced hemofiltration decreased pulmonary (decreased A-a gradient and time to extubation) and coagulation (decreased postoperative blood loss) dysfunction and incidence of pyrexia.</td>
</tr>
<tr>
<td>Leukocyte depletion</td>
<td>Leukocyte depletion of blood cardioplegia (17) versus control [dummy filters] (15) in adult CABG patients with left ventricular dysfunction</td>
<td>Leukocyte depletion of blood cardioplegia attenuated myocardial injury [troponin T concentrations] and improved early myocardial function [LVEF; use of inotropes]; no effect on postoperative hemodynamics [HR, MAP, CI]. Leukocyte depletion following cross-clamp release did not decrease pulmonary [duration of mechanical ventilation] or hemostatic [mediastinal drainage; postoperative Hb; autologous blood transfused] dysfunction. Feasibility study with no significant intergroup difference in clinical parameters. Trend to attenuation of pulmonary dysfunction [postoperative PaO₂, duration of endotracheal intubation] and reduced hospital stay.</td>
</tr>
<tr>
<td>Roth et al., 2000</td>
<td>Leukocyte depletion control [standard arterial line filter] (20) following release of aortic cross-clamp in low-risk elective CABG patients</td>
<td>Leukocyte depletion control [standard arterial line filter] following release of aortic cross-clamp in low-risk CABG patients with left ventricular function. No effect on postoperative hemodynamics [HR, MAP, CI]. Leukocyte depletion following cross-clamp release did not decrease pulmonary [duration of mechanical ventilation] or hemostatic [mediastinal drainage; postoperative Hb; autologous blood transfused] dysfunction. Feasibility study with no significant intergroup difference in clinical parameters. Trend to attenuation of pulmonary dysfunction [postoperative PaO₂, duration of endotracheal intubation] and reduced hospital stay.</td>
</tr>
</tbody>
</table>

(continues)
Table 5. (continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>Intervention</th>
<th>Main Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>van de Watering et al. 1998</td>
<td>Freshly leukocyte-depleted (305) versus stored leukocyte-depleted (303) versus non-leukocyte-depleted (306) transfused blood in adult patients for CABG/heart valve or combined operations</td>
<td>Leukodepletion of transfused blood significantly reduced the overall 60-day mortality; dramatic reduction in death from MODS; reduced postoperative infection rate in patients who received more than 3 units of blood.</td>
</tr>
<tr>
<td>Hurst et al. 1997</td>
<td>Neutrophil-specific (11) versus standard blood filter (13) during CPB for adult elective open heart valve surgery</td>
<td>No significant intergroup difference in clinical parameters, including respiratory [PaO2, lung function tests] or cardiovascular [CI, LVEF, hemodynamic variables, use of inotropes] dysfunction, or in duration of ICU or hospital stay.</td>
</tr>
<tr>
<td>Gu et al. 1996</td>
<td>Leukocyte depletion (20) of residual heart–lung machine blood at the end of CPB versus control (no intervention) (10)</td>
<td>Leukocyte depletion improved postoperative lung gas exchange. No intergroup difference in pulmonary hemodynamics, postoperative blood loss, or duration of intubation, ICU, or hospital stay.</td>
</tr>
<tr>
<td>Morioka et al. 1996</td>
<td>Leukocyte and platelet depletion (21) from start of surgery to 60 min after aortic clamp release versus control (no intervention) (21) in adult patients for CABG or heart valve surgery</td>
<td>Leukocyte and platelet depletion attenuated postoperative respiratory dysfunction [A-a gradient; respiratory index]. Most benefit on subgroup analysis in patients with lower preoperative Po2 and long CPB time.</td>
</tr>
<tr>
<td>Sawa et al. 1996</td>
<td>Leukocyte-depleted terminal blood cardioplegia (10) versus terminal blood cardioplegia (10) versus whole blood cardioplegia (10) in patients with left ventricular hypertrophy undergoing heart valve surgery</td>
<td>Leukodepletion of terminal blood cardioplegia decreased myocardial injury [histologic indices; CK-MB concentrations] and improved cardiac function [less inotropic support]; no effect on postoperative hemodynamics [CI; PCWP].</td>
</tr>
<tr>
<td>Johnson et al. 1995</td>
<td>Leukocyte-specific (16) versus standard blood filter (16) in adult CABG patients</td>
<td>Leukocyte depletion resulted in transient (&lt; 24 h) improvements in pulmonary [intrapulmonary shunt] and cardiovascular [MAP] function.</td>
</tr>
<tr>
<td>Plateletpheresis</td>
<td>Preoperative platelet-rich plasma harvest with reinfusion after CPB (20) versus control (no harvest) (20) in patients undergoing CPB for repeat CABG</td>
<td>Plateletpheresis attenuated pulmonary dysfunction [improved gas exchange; decreased duration of mechanical ventilation]; decreased ICU stay; improved hemostatic function [decreased blood loss; decreased blood transfusions].</td>
</tr>
<tr>
<td>Lemmer et al. 1996</td>
<td>High dose (173) versus low dose (180) versus pump prime–only (173) doses of aprotinin versus placebo (178) in low-risk CABG patients</td>
<td>Aprotinin reduced bleeding and transfusion requirements. No between-group differences in mortality or the incidences of renal failure, strokes, or definite myocardial infarctions. Pump prime–only dose was associated with a small increased incidence of MI.</td>
</tr>
<tr>
<td>Levy et al. 1995</td>
<td>High-dose aprotinin (61) versus low-dose aprotinin (60) versus pump prime aprotinin (68) versus placebo (65) in patients for repeat CABG</td>
<td>High- and low-dose aprotinin reduced need for blood and blood product transfusion, and reduced incidence of stroke. No intergroup difference in rate of MI, cardiovascular complications renal dysfunction, or mortality.</td>
</tr>
<tr>
<td>Wendel et al. 1995</td>
<td>High-dose aprotinin (20) versus placebo (20)</td>
<td>Aprotinin decreased postoperative myocardial injury [troponin T concentrations].</td>
</tr>
<tr>
<td>Pentoxifylline</td>
<td>Pentoxifylline (15) versus placebo (25) in high-risk patients [APACHE score ≥ 19 on first postoperative day] after major cardiovascular surgery (&gt; 90% cardiac)</td>
<td>Pentoxifylline decreased duration of mechanical ventilation, decreased the incidence of renal dysfunction and need for hemofiltration/dialysis and length of ICU stay. There was no intergroup difference in duration of hospital stay or mortality.</td>
</tr>
</tbody>
</table>

(continues)
may be utilized in the presence or absence of CPB. The surgical incision may affect the inflammatory response generated, with reduced complement activation following limited anterolateral thoracotomy as opposed to median sternotomy, although this is disputed. One nonrandomized study of patients undergoing mitral valve surgery via limited right anterolateral thoracotomy and port access suggested that this group resumed work or normal activity earlier than comparable patients undergoing conventional median sternotomy. However, the efficacy of minimally invasive cardiac surgery remains to be clearly demonstrated. At present, operating times are considerably longer with minimal access techniques.

Anesthesiology, V 97, No 1, Jul 2002
**Drew-Anderson Technique.** An intermediate, less invasive approach may be to use the patient’s own lungs as an oxygenator via bilateral extracorporeal circulation. This technique, introduced by Drew and Anderson, allows good surgical access yet avoids the need for an artificial oxygenator. A recent randomized clinical trial, focusing on this method as a means of attenuating the inflammatory response, reported decreased concentrations of IL-6 and IL-8 and an attenuation of postoperative hemostatic and pulmonary dysfunction (table 5).

**Summary.** Since aortic cross-clamping and CPB were universally used for all forms of cardiac surgery, their relative role in the pathogenesis of postoperative complications has been unclear. OPCAB will help to delineate the intrinsic effects of bypass on the inflammatory response to cardiac surgery. OPCAB and minimally invasive cardiac surgery have demonstrated encouraging short-term benefits in the small-scale clinical studies of low-risk patients carried out to date, but clinical studies have not been carried out in the high-risk groups most likely to benefit. Finally, concerns regarding the quality of graft anastomoses achieved with OPCAB or minimal access techniques remain to be addressed.

**Strategies to Improve Biocompatibility of the Extracorporeal Circuit**

Improving the biocompatibility of the CPB circuit in order to reduce contact activation of the immune system, particularly the complement cascade, may be a useful strategy to limit the inflammatory response. Potential approaches include use of more biocompatible materials in the circuit or modifications of the surface of the circuit by coating with compounds that are less immunogenic.

**Heparin-coated Circuits.** Heparin-coated CPB circuits (HCCs) enhance biocompatibility, reduce contact activation, and may decrease postoperative cardiovascular, respiratory, hemostatic, and neurologic dysfunction. The method by which the circuit is coated and the type of heparin used may have implications for its effects on the coagulation and complement systems. The Duraflo II HCC, which uses ionically bonded unfractionated heparin (Duraflo II surface; Baxter Healthcare Corp., Irvine, CA), reduces kallikrein and complement activation but is less effective in attenuating coagulation or fibrinolysis. The Carmeda Bioactive Surface system (CBAS; Medtronic Inc., Minneapolis, MN) uses end-attached covalently bonded heparin that has been fragmented by treatment with nitric acid. The Carmeda circuit appears superior to the Duraflo II in reducing complement, neutrophil activation, and endothelin-I concentrations.

Clinical studies to date suggest that the beneficial effects of HCCs are confined to high-risk patients (table 5). In low-risk patients, HCCs decrease neutrophil activation, decrease myocardial injury, and reduce complement activation. The largest study to date in low-risk patients revealed no overall clinical benefit, although subgroup analysis suggested that women and patients with prolonged aortic cross-clamp times may benefit from HCC. Duraflo II HCCs decreased the duration of ventilatory support and ICU stay and reduced the incidence of poor outcome (death or prolonged ICU stay) in a large study of high-risk patients. However, a similar but smaller study failed to confirm these benefits. The benefits of HCC-based technology may be
more apparent in patients with preexisting organ dysfunction.49 Outcome may be enhanced when Duraflor HCCs are combined with the use of silicone-coated oxygenators.299 HCC may attenuate the proinflammatory response more markedly and may have greater myocardial protective effects where perfusion times are prolonged, especially in heart and heart–lung transplantation.300

Other Strategies. Other strategies to improve biocompatibility having therapeutic potential include coating of circuitry with phosphatidylcholine,301 silicone,302 synthetic proteins303 and polymers,304 or surface-modifying additives.305,306 Decreasing oxygenator surface area may also decrease activation of the inflammatory response.307

Strategies to Reduce Endotoxemia

Selective Digestive Decontamination. Selective digestive decontamination (SDD) is a technique to reduce the gut content of enterobacteria. This is achieved by preoperative administration of oral nonabsorbable antibiotics such as polymyxin E, tobramycin, and amphotericin B, and has been demonstrated to reduce plasma concentrations of endotoxin, TNF-α, and IL-6 in patients undergoing CPB.53 A recent metaanalysis of SDD suggests that it reduces rates of postoperative infection, but not mortality, in patients undergoing cardiac surgery.308 Since mortality reduction with SDD in critically ill patients appears to be related to baseline mortality risk,309 trials of SDD in cardiac surgery thus far contain too many low-risk patients, resulting in inadequate study power. SDD may prove worthwhile in high-risk cardiac surgical patients,310 but since its use raises both practical issues (notably the logistics of performing it) and theoretical concerns (changes in bacterial flora, emergence of resistance), its adoption is unlikely pending further studies.

Enteral Nutrition and Immunonutrition. Hypoalbuminemia and low body mass index independently predict increased morbidity and mortality after cardiac operations.310 In an early study, well-nourished patients undergoing valve surgery had a much shorter hospital stay compared to those with preoperative malnutrition.311 Laboratory evidence in animals suggests that protein-calorie malnutrition decreases left ventricular function312 and that myocardial glycogen concentration correlates with left ventricular function following CPB.313

The beneficial role of early institution of enteral nutrition, particularly “immunonutrition,” which contains supplements such as arginine, purine nucleotides, and ω-3 fatty acids, which are considered to enhance immune function, has been established in other groups of postoperative and critically ill patients. In critically ill patients, immunonutrition reduced the duration of ICU and hospital stay, infectious complications, duration of SIRS, and mechanical ventilation compared to patients receiving conventional nutrition.314 In patients for elective gastrointestinal surgery, preoperative and postoperative immunonutrition has beneficial effects on immune function, complication rate, and duration of hospital stay.315,316 The use of glutamine supplementation may improve survival of patients with organ failure who require parenteral nutrition.317

There is no information available concerning the effect of nutritional support in patients undergoing cardiac surgery who have a complicated postoperative course.

Strategies to Maintain Hemodynamic Stability and Organ Perfusion

Perioperative hemodynamic instability, especially post-CPB low cardiac output syndrome, is a marker for later adverse outcome and death. Splanchnic perfusion abnormalities, as measured by tonometrically derived intramucosal pH and PaCO₂, strongly predict postoperative morbidity in cardiac surgical patients.320 Covert hypovolemia may exacerbate splanchnic hypoperfusion during and after CPB, and this may be treatable by increasing intravascular volume. Other therapeutic options include pharmacologic and mechanical circulatory support.

Optimization of intravascular volume status may be beneficial even in apparently stable patients.318 In low-risk cardiac surgical patients, intraoperative intravascular volume expansion with the objective of maximizing stroke volume resulted in improved gastric intramucosal pH values, less hemodynamic interventions, lower complication rates, and shorter ICU and hospital stay.319 Furthermore, low intraoperative filling pressures and high pressor usage may contribute to increased gut permeability and endotoxia.319 Excessive hemodilution during CPB may play a role in the pathogenesis of post-CPB low cardiac output syndrome. In a multicenter observational study, excessively low hematocrit values during CPB independently predicted in-hospital mortality, need for intraaortic balloon pump usage, and return to bypass following failed separation.320

There are no outcome-based data to support the routine use of pharmacologic interventions to maximize splanchnic perfusion in patients undergoing cardiac surgery. However, patients failing to meet preset hemodynamic goals may benefit from such measures. In a recent randomized trial in which early postoperative cardiovascular function was optimized, using preload augmentation and dobutamine to normalize mixed venous oxygen saturation values and lactate concentration, optimized patients had reduced length of hospital stay and reduced organ dysfunction at the time of discharge compared with patients receiving standard care.321 Pharmacologic interventions to maximize splanchnic perfusion may attenuate the inflammatory response. Immune cells contain type IV and type III phosphodiesterase,322 and phosphodiesterase inhibitors appear to directly limit inflammatory activation and organ dysfunction in sepsis models.322,323 Milrinone attenuates the reduction in gas-

Anesthesiology, V 97, No 1, Jul 2002
tric intramucosal pH, reduces both venous and hepatic endotoxin concentrations, and may decrease postoperative IL-6 concentrations in healthy patients undergoing cardiac surgery, although this has been disputed. Dopexamine attenuates the postoperative increase in IL-6 concentrations and reduces gastrointestinal permeability, but does not improve splanchnic perfusion (as measured by intramucosal pH) or decrease plasma endotoxin concentrations following CPB.

The elective use of mechanical circulatory support, such as preoperative intraaortic balloon pump, in selected high-risk patients, especially the elderly, and those with severe left ventricular dysfunction, may reduce the incidence of postoperative low cardiac output syndrome, mortality, and ICU stay without significant increases in morbidity or cost.

**Filtration Techniques**

**Hemofiltration.** Hemofiltration is a process that uses ultrafiltration, i.e., the processes of conversion, osmosis under a hydrostatic pressure gradient, to remove fluid and low-molecular-weight substances from plasma. Initially introduced to treat patients with renal failure and to correct accumulation of extravascular water following CPB, hemofiltration appears to exert beneficial antiinflammatory effects, particularly in pediatric patients. Hemofiltration may remove proinflammatory mediators, with reductions in postoperative TNF-α, IL-1, IL-6, IL-8, C3a, and myeloperoxidase concentrations. This technique improves hemodynamic stability and early postoperative oxygenation and reduces postoperative blood loss and duration of mechanical ventilation in pediatric cardiac surgery. Hemofiltration may reduce pulmonary hypertension after congenital heart surgery, possibly by facilitating removal of endothelin-1. Modified hemofiltration after CPB improves intrinsic left ventricular systolic function and diastolic compliance, increases blood pressure, and decreases inotropic drug use in the early postoperative period in infants.

Hemofiltration appears to be less effective in adults, with no decrease observed in postoperative blood loss, average bank blood transfused, postoperative weight gain, length of stay, or overall patient costs. Hemofiltration in adults undergoing CPB is less effective in removing proinflammatory cytokines than in pediatric patients, perhaps explaining its apparent lack of efficacy in this population.

**Leukocyte Depletion.** Leukocytes play a central role in the inflammatory response to cardiac surgery. Leukocyte depletion during cardiac surgery, by means of leukocyte-specific filters, decreases circulating leukocyte and platelet concentrations and attenuates indices of oxidative stress and inflammation. There is increasing evidence that leukocyte depletion may attenuate pulmonary and myocardial injury following CPB. Benefit appears most consistent in patients with risk factors such as left ventricular dysfunction, urgent surgery, or long CPB time. Leukodepletion has been shown to improve postoperative respiratory function in CPB patients, particularly in patients with a low preoperative oxygenation capacity or long CPB time. In addition, leukocyte depletion of the residual heart-lung machine blood, which contains high quantities of activated leukocytes, prior to retransfusion, improved lung function in patients undergoing elective CABG. Leukodepletion during CPB, combined with leukodepletion of transfused blood, decreased indices of myocardial cell injury in patients undergoing urgent CABG for unstable angina. Conversely, in low-risk patients, depletion of activated neutrophils during CPB did not confer clinical benefit. Limiting leukocyte depletion to the “reperfusion phase” of CPB (following aortic unclamping) does not appear to confer any clinical benefit in CABG patients.

Leukocyte depletion of blood cardioplegia alone attenuated myocardial cell injury and improved early myocardial function in patients with left ventricular dysfunction undergoing CABG with CPB. Leukodepletion of terminal blood cardioplegia, (i.e., blood cardioplegia administered for 10 min immediately prior to aortic unclamping as an adjunct to crystalloid cardioplegia) decreased myocardial injury and improved cardiac function in patients with left ventricular hypertrophy undergoing valve surgery. The immunomodulatory effects of leukocytes in allogeneic blood has focused attention on the potential benefits of leukodepleting stored blood. A large-scale clinical trial conducted in CPB patients demonstrated that leukocyte depletion of transfused blood significantly reduced the overall 60-day mortality. The difference in mortality was predominantly due to a dramatic reduction in noncardiac causes of death, particularly multiorgan failure. In addition, leukodepletion reduced the postoperative infection rate in patients who received more than 3 units of blood.

**Agents That May Suppress the Inflammatory Response**

**Serine Protease Inhibitors.** Many effector proteins of the cytokine, complement, and hemostatic cascades are serine proteases, i.e., when activated they catalyze the next step in the cascade by hydrolyzing and activating further proteins, a process termed “cascade amplification.” Control processes that limit inflammation to the sites of injury and reduce systemic inflammation include serine protease inhibitors. Aprotinin is the best known and studied of these inhibitors.

**Aprotinin.** Aprotinin, a complex polypeptide and nonspecific serine protease inhibitor, has clearly been demonstrated to prevent excessive blood loss during cardiac surgery. In addition, aprotinin has multiple actions that may suppress the inflammatory response,
particularly at higher dosages. Antiinflammatory effects include attenuation of platelet activation, maintenance of platelet function, decreased complement activation, inhibition of kallikrein production, decreased release of TNF-α, IL-6, and IL-8, inhibition of endogenous cytokine-induced iNOS induction, decreased CPB-induced leukocyte activation, and inhibition of up-regulation of monocyte and granulocyte adhesion molecules.95,353

In clinical studies, high-dose aprotinin reduces postbypass myocardial ischemia and myocyte damage, and length of hospital stay in high-risk patients. However, a pump-prime-only dose of aprotinin may increase the risk of postoperative myocardial infarction. Levy et al. found no such increase in the incidence of perioperative myocardial infarction in patients undergoing repeat CABG. Concerns over graft patency following aprotinin therapy have been reduced by the IMAGE trial, which found no difference in early (10-day) patency rates for internal mammary artery grafts or for saphenous vein grafts after controlling for confounding factors. Aprotinin may reduce pulmonary and cerebral injury following CPB. Aprotinin decreases experimental CPB-induced and cytokine-induced bronchial inflammation and was demonstrated to attenuate lung reperfusion injury following CPB in one small clinical study. An early report of use of aprotinin in high-risk cardiac surgery patients indicated an incidence of fatal stroke of 0.5%, compared to rates of 2-3% in contemporary studies that did not use aprotinin. A multicenter trial of repeat CABG patients found that the incidence of stroke was reduced with high- or low-dose aprotinin. Lemmer et al. failed to show a significant decrease in the incidence of stroke with three different dosage regimens in their large-scale multicenter study. However, a pooled analysis of six trials, including the aforementioned trials, found that high-dose aprotinin significantly reduced the incidence of stroke. Initial concerns over the potential for adverse effects of aprotinin on renal function appear unfounded.

No single study of aprotinin has clearly demonstrated improved patient outcome to date. However, a recent metaanalysis reported that aprotinin reduces surgical blood loss, allogeneic blood transfusion, and the need for rethoracotomy, and decreases perioperative mortality almost twofold, with no increase in the risk of myocardial infarction. These data provides strong support for the use of aprotinin in patients undergoing cardiac surgery.

Pentoxifylline. Pentoxifylline is a nonspecific phosphodiesterase inhibitor with diverse antiinflammatory effects, many of which may be mediated by inhibition of phosphodiesterase IV. These include attenuation of TNF-α release in sepsis, decreased endotoxin and cytokine activation of neutrophils, reduction of indices of myocardial cellular injury, and a more reactive and injurious free radical. Free radical scavengers and antioxidants. Generation of reactive oxygen species (ROS) (hydrogen peroxide and the superoxide and hydroxyl radicals) occurs upon reperfusion following bypass, and these may be important contributors to tissue injury. Leukocytes activated during bypass may also release substantial amounts of cytokotoxic ROS. When present in equimolar concentrations, superoxide and NO may combine form peroxynitrite, a more reactive and injurious free radical. Myocardial antioxidant enzymes, including glutathione reductase, superoxide dismutase, and catalase, are activated in proportion to the degree of myocardial ischemia and reperfusion injury. Host antioxidants become depleted after CPB, presumably as a result of consumption by free radicals. When ROS production exceeds host defense scavenging capacity, cellular injury results. There is an inverse correlation between preoperative total plasma antioxidant status and lipid peroxidation, the latter of which is directly correlated with indices of myocardial cellular injury. Furthermore, post-CPB coronary endothelial dysfunction appears to be partially mediated by ROS. Free radical scavengers, such as enzymatic scavengers, antioxidants, and iron chelators, may be potentially useful therapeutic adjuncts to control the deleterious effects of the inflammatory response. High-dose vitamin C (ascorbic acid) has been demonstrated to effectively scavenge free radicals, decreasing cell membrane lipid peroxidation and indices of myocardial injury, and improving hemodynamics with a shorter ICU and hospital stay. Vitamin E (α-tocopherol) reduces plasma concentrations of hydrogen peroxide, a marker of free radical concentrations, and decreases cell membrane lipid peroxidation following CPB. Preoperative supplementation with a combination of ascorbic acid, α-tocopherol, and allopurinol reduced cardiovascular dysfunction in both stable and unstable conditions.
patients undergoing CABG. Unstable CABG patients sustained less myocardial injury and a decreased incidence of perioperative myocardial infarction.\textsuperscript{384} A more recent trial of combined \( \alpha \)-tocopherol and ascorbic acid supplementation in CABG surgery revealed no detectable decrease in myocardial injury.\textsuperscript{15}

High-dose N-acetylcysteine before or during bypass appears to act as a free radical scavenger\textsuperscript{385} and reduces the neutrophil oxidative burst response\textsuperscript{385} and elastase activity.\textsuperscript{386} In an early interventional trial in patients with established acute lung injury, N-acetylcysteine was shown to improve oxygenation and lung mechanics, although no impact on progression to acute respiratory distress syndrome was noted.\textsuperscript{387}

Allopurinol is an inhibitor of the enzyme xanthine oxidase, a pivotal generator of free radicals during reperfusion injury. Allopurinol may decrease myocardial formation of cytotoxic free radicals,\textsuperscript{380,388} lower markers of myocardial cellular injury,\textsuperscript{389} and improve recovery of myocardial function following CPB.\textsuperscript{390,391} However, other studies have demonstrated no improvement in either myocardial function\textsuperscript{392} or myocardial cellular injury with allopurinol use,\textsuperscript{388,393} casting doubt on its therapeutic potential.

Pretreatment of patients with mannitol reduces myocardial formation of cytotoxic free radicals after CPB in humans.\textsuperscript{380} Other free radical scavengers-antioxidants that appear from animal studies to possess therapeutic potential include methionine, reduced glutathione, dimethylthiourea, mercaptopyrroleglycine, superoxide dismutase, catalase, and desferrioxamine.\textsuperscript{381,394–397}

**Immunomodulation**

**The Corticosteroid Controversy.** The use of corticosteroids in the context of CPB continues to be controversial because of their potential risks. Past negative experience, particularly with the use of corticosteroids in septic shock,\textsuperscript{398} has served to emphasize the need for caution when considering corticosteroid use, even in noninfective inflammatory conditions, where their potential antiinflammatory actions might be expected to be beneficial. However, there have been significant advances in our understanding of the molecular mechanisms by which corticosteroids might blunt the inflammatory response to cardiac surgery.

Corticosteroid pretreatment may blunt the inflammatory response in humans by several distinct mechanisms. Administration of glucocorticoids prior to CPB may attenuate endotoxin release\textsuperscript{399} and complement activation.\textsuperscript{400,401} Methylprednisolone lowers post-CPB concentrations of the proinflammatory cytokines TNF-\( \alpha \),\textsuperscript{349} IL-6, and IL-8,\textsuperscript{402} and increases concentrations of the antiinflammatory cytokines IL-10 and IL-1ra,\textsuperscript{402} but not IL-4.\textsuperscript{403} Corticosteroids also attenuate post-CPB leukocyte activation,\textsuperscript{20} neutrophil adhesion molecule up-regulation,\textsuperscript{349} and pulmonary neutrophil sequestration.\textsuperscript{401}

Prebypass administration of methylprednisolone in aprotinin-treated patients improves early postoperative indices of pulmonary, cardiovascular, hemostatic, and renal function.\textsuperscript{404} Glucocorticoid pretreatment may improve cardiac performance\textsuperscript{405} and reduce evidence of bronchial inflammation following CPB.\textsuperscript{406} Low-dose methylprednisolone in the pump prime solution appears to attenuate myocardial cell damage.\textsuperscript{407} Dexamethasone 213,214 and methylprednisolone 212,215 decrease the incidence of postoperative fever. In animal studies, corticosteroid pretreatment improved several indices of lung injury, including pulmonary compliance, alveolar-arterial gradient, pulmonary vascular resistance, and extracellular fluid accumulation.\textsuperscript{408} However, the ability of corticosteroid pretreatment to attenuate post-CPB pulmonary inflammation,\textsuperscript{409} endotoxemia,\textsuperscript{400} and complement activation is disputed.\textsuperscript{20,410}

The clinical implications of corticosteroid use are not yet fully elucidated, and clear benefit is not yet demonstrated. The dosage, formulation, and timing of administration of corticosteroids may be critical, and differences in dosage regimens may explain conflicting results. Preoperative combined with prebypass administration may be superior to prebypass administration alone.\textsuperscript{408} It is premature to advocate the use of corticosteroids in the absence of proven outcome benefit, determination of optimal dosage regimens, and characterization of harmful effects, e.g., immunosuppression, which may result from their use.

**Cyclooxygenase Inhibitors.** Aspirin, the prototype nonsteroidal antiinflammatory drug (NSAID), is widely used in cardiac surgical patients for the purposes of pain relief and antiplatelet activity. However, the potential for NSAID’s inhibitors to attenuate the inflammatory response to cardiac surgery has not been widely evaluated in clinical trials. Traditional NSAIDs, such as indomethacin, inhibit both the constitutive cyclooxygenase 1 (COX-1) as well as COX-2, the inducible isoform activated by inflammatory stimuli. Nonspecific COX inhibition attenuates the increase in pulmonary vascular resistance and ALI\textsuperscript{411} and reverses pulmonary microvascular dysfunction\textsuperscript{412} in CPB models. One older clinical study of indomethacin demonstrated that it decreased the duration of postoperative fever, chest pain, malaise, and myalgias following CPB.\textsuperscript{211} However, inhibition of COX-1 appears to increase free radical-generated isoprostane formation, which aggravates postischemic myocardial dysfunction.\textsuperscript{413,414}

Specific COX-2 inhibitors exhibit considerable potential to attenuate the inflammatory response following cardiac surgery. COX-2 has been implicated in the pathogenesis of adverse events after cardiac surgery.\textsuperscript{415,416} COX-2 is up-regulated following CPB,\textsuperscript{415} in multiple tissues, including the brain,\textsuperscript{416} while COX-2 products, particularly thromboxanes\textsuperscript{417} and vasoconstrictor prostaglandins, are increased.\textsuperscript{412} COX-2 up-
regulation following experimental CPB may contribute to postoperative coronary vasospasms and increased pulmonary vascular resistance. In addition, myocardial COX-2 is up-regulated during cardiac allograft rejection and myocardial infarction and contributes to endotoxin-induced myocardial depression. Inhibition of COX-2 attenuates the myocardial inflammatory response during cardiac allograft rejection, reduces endothelial dysfunction following myocardial ischemia and reperfusion, and improves cardiac function in experimental myocardial infarction. In addition, COX-2 inhibition decreases endotoxin-induced myocardial depression and lung ischemia and reperfusion injury. However, the clinical efficacy of specific COX-2 inhibitors in attenuating the inflammatory response to cardiac surgery remains to be determined.

**Complement-directed Therapies.** Therapies that utilize endogenous soluble complement inhibitors may be a suitable approach to reduce contact activation and thereby control the inflammatory response. A recent two-stage randomized clinical trial of a monoclonal antibody specific for human C5 demonstrated its efficacy and safety in patients undergoing CPB. The generation of activated complement mediators and leukocyte adhesion molecule formation was inhibited in a dose-dependent manner. Furthermore, C5 inhibition resulted in a dose-dependent reduction in myocardial injury, postoperative cognitive deficits, and coagulation dysfunction. These data suggest that C5 inhibition may represent a promising therapeutic modality for preventing complement-mediated inflammation and tissue injury in patients undergoing CPB. Compstatin, a recently discovered peptide inhibitor of complement, may have the potential to prevent complement activation during and after cardiac surgery. In preliminary primate studies, compstatin completely inhibited in vivo heparin-protamine-induced complement activation without adverse effects.

Other promising strategies include the C1 inhibitor, recombinant soluble inhibitor-1, monoclonal antibodies to C3 and C5a, and strategies that attenuate complement receptor 3-mediated adhesion of inflammatory cells to the vascular endothelium. Utilization of membrane-bound complement regulators may also be feasible by means of transfection techniques.

**Antimediator Therapies.** Direct antimediator therapies that focus upon the endotoxin molecule itself and the proinflammatory cytokine cascade following CPB offer new approaches. However, the complex pathway observed in patients with SIRS does not appear to readily respond to antimediator therapy. Multicenter clinical trials blocking endotoxin and proinflammatory mediators such as IL-1 or TNF-α conducted in SIRS patients have shown no benefit in reducing mortality secondary to sepsis. Reasons for the relative failure of immunomodulatory therapies to date may include the timing of intervention, the heterogeneous nature of the inflammatory response, and the reciprocating and redundant nature of the proinflammatory cascades. High circulating concentrations of anti-inflammatory mediators, such as the cytokine antagonists IL-1ra, TNFsr1, and TNFsr2, may also limit the efficacy of therapies that aim to augment natural defenses against endotoxin or the proinflammatory cytokines.

The experience with antimediator therapy in sepsis suggests a need for caution in considering the application of these therapies to control the inflammatory response to CPB. Nevertheless, antimediator therapies may be worthy of investigation for two reasons. These therapies may enhance our understanding of the inflammatory process following CPB. Their administration prior to bypass, in order to modulate the inflammatory pathways at their earliest stages, might constitute a more successful approach than that used in other clinical scenarios, such as in sepsis, where the inflammatory response may be already well developed before antimediator therapy is possible.

**Therapies to Attenuate Endothelial Injury.** Current evidence suggests that therapeutic efforts in patients with SIRS should include modulation of endothelial cell function. Better definition of the molecular mechanisms of endothelial cell activation may facilitate development of therapies that allow selective inhibition of vascular endothelial activation. Adhesion molecule blockade may prevent neutrophil adherence during the first 24 h after CPB, thereby preventing the neutrophils from mediating widespread organ damage. In this regard, blockade of endothelial and neutrophil selectin adhesion molecules results in marked attenuation of cerebral injury in an animal model of CPB and deep hypothermic circulatory arrest. Inhibition of neutrophil adhesion markedly reduced pulmonary injury in a porcine model of CPB. However, there may be limits to this approach because adhesion molecule blockade increases susceptibility to infection. Finally, methods to prevent nuclear localization of the transcriptional activator NF-κB in order to prevent endothelial cell activation are also being studied in animal models.

**Future Research Directions**

The development of organ dysfunction following CPB remains an indicator of poor outcome despite advances in resuscitation, drug, and adjunctive therapies. Organ support therapies, e.g., mechanical ventilation, can sustain life but may impair both local and remote organ function, e.g., ventilator-associated lung injury. A better understanding of the inflammatory response to cardiac surgery may be the key to development of successful strategies to minimize patient morbidity. With some exceptions, such as recent data on HCCs and inhibition.
of complement activity, the link between the inflammatory response and adverse clinical sequelae, while persuasive, is currently associative rather than causative. A primary research priority must be to establish direct causal links between (and mechanistic insights into) the inflammatory response to surgery or CPB and clinical outcome. Therapeutic interventions cannot be justified in the absence of clear cause-and-effect relations.

There remains a need to document clear clinical benefits from interventions designed to modify the inflammatory response. Modulation of the human inflammatory response has always been difficult, primarily as a result of our incomplete understanding of this response, and may lead to unexpected sequelae. The complexity of the inflammatory response is a significant obstacle to identification of the mechanism(s) by which alteration of a particular aspect of the response may affect clinical outcome. Indiscriminate inhibition—prevention of the inflammatory response to CPB may have detrimental effects, such as loss of appropriate wound healing and defenses against infection. Certain proinflammatory cytokines, such as IL-1β and even endotoxin appear to have poorly understood protective effects. In this regard, IL-1β pretreatment protects against subsequent myocardial ischemia and reperfusion injury. The emphasis of future strategies must therefore be on the control of, rather than the simple inhibition of, the inflammatory response to CPB.

Further research is required to determine why certain patients appear to be at increased risk of clinically important bypass-induced injury. Monitoring tools such as gastric tonometry and other indicators of systemic organ hypoperfusion in CPB patients have provided physiologic insights, but their role in therapy remains to be clarified. Preoperative or early perioperative identification of patients most likely to develop adverse clinical sequelae from SIRS would allow focusing of investigative, preventive, and therapeutic maneuvers, and should be a research priority.

The heterogeneity of the patient population undergoing CPB is well illustrated by the finding of a near 20-fold difference in mortality (1.8% vs. 54.3%) for first time elective versus high-risk reoperative coronary artery bypass procedures. Many studies of therapeutic interventions have been carried out in relatively low-risk patients, in whom the risk of adverse postoperative events might be expected to be minimal. It is possible that beneficial effects of these therapeutic strategies may be diluted by studies that include low-risk patients. Therefore, future investigations of interventions to control the inflammatory response to CPB may be best focused on patients at high risk of postoperative organ dysfunction. Future studies should utilize direct clinical indicators of organ injury as outcome measures rather than simply measurement of mediator concentrations as surrogates of injury. Many of the previously conducted clinical trials do not contain adequate patient numbers to detect meaningful differences in outcome. There is a clear need for large-scale clinical trials of more promising strategies such as selective gut decontamination, maintenance of splanchnic perfusion, drug therapies including corticosteroid pretreatment, aprotinin, acadesine, and adjunctive measures, such as hemofiltration, and use of biocompatible materials in the extracorporeal circuit. These trials, restricted to patients at significant risk of perioperative morbidity, may have to be completed using multiple centers. Finally, more investigation is needed to determine the efficacy and safety of off-pump cardiac surgery, and new methods for myocardial protection in this context need to be developed.

Conclusions

Cardiac surgery evokes a generalized inflammatory response in all patients, with serious clinical consequences in a minority, despite advances in pharmacology, perfusion technology, cardiovascular monitoring, and anesthetic and surgical technique. This is most clearly evident with regard to postoperative pulmonary and cardiovascular dysfunction. The etiology of these events is probably a composite of unstable peribypass hemodynamics, global myocardial ischemia, suboptimal organ perfusion during CPB, and immune events related to exposure to extracorporeal circulation per se. A balanced, controlled inflammatory response is potentially beneficial, aiding host defenses against infection and facilitating wound healing, but loss of control of the inflammatory response may herald the onset of SIRS and single or multiple organ dysfunction.

The complex interaction of key proinflammatory and antiinflammatory components of the inflammatory response, the significance of alterations in the magnitude or time course of release, and their relation to the clinical sequelae seen following CPB remain to be fully elucidated. Further work to establish direct causal links between the inflammatory response to CPB and organ dysfunction may lead to mechanistic insights and in turn stimulate the development of successful preventive and therapeutic strategies. The increasing use of minimally invasive surgical techniques such as OPCAB will contribute to these insights, particularly the relative roles of CPB and peribypass events. The link between interventions and clinical benefit is gradually being established for several strategies, including improved circuit biocompatibility, maintenance of splanchnic perfusion, hemofiltration (in the pediatric population), aprotinin, and corticosteroid therapy. The need to better characterize and focus therapeutic interventions on the patient at risk of MODS following CPB is imperative.

The goal of modulation of the perioperative inflammatory response is to attenuate its deleterious effects while
preserving the ability of the patient to mount an appropriate defense to the physiologic trespasses of the perioperative period. Although knowledge is growing about the role of altered immune function, the role of immuno-modulatory therapies will remain investigational (especially in view of the failures of these therapies in recent sepsis trials) until the initiating events in postoperative SIRS become clearer.

The authors thank Wl Gamble, Medical Illustrator, Montreal, Quebec, Canada, for his expert art work in relation to figure 4.

References

13. Roach GW, Kanchuder M, Xiang YC, Mouzaki S, Yee D, Versluis G, Duffey SG, Raftery TL, Hedges M, Colby B, Moore MC, Parry M, Nester E: The role of altered immune function, the role of immuno-modulatory therapies will remain investigational (especially in view of the failures of these therapies in recent sepsis trials) until the initiating events in postoperative SIRS become clearer.

Anesthesiology, V 97, No 1, Jul 2002

444

LAFFEY ET AL.


176. Biltinger TV, Finimian C, Stefano GB: Morphine’s immunoreulatory actions are not shared by fentanyl. Int J Cardiol 1998; 64:601–6


187. Holappa MP, Malave A, Lowy MK, Yim GK. Central and peripheral anti-inflammation techniques by clindamycin and structurally related imidazolidin analog. J Pharmacol Exp Ther 1984; 229:399–403


198. Hesthetic M, Salmi LR, Frenning EM, VanDemark AW, Rubens F, Laupacis A: A meta-analysis of the effectiveness of cell salvage to minimize...
CARDIAC SURGERY AND THE INFLAMMATORY RESPONSE

249


